Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2-aminobenzoyl-LPATG-diaminopropionic acid + H2O
2-aminobenzoyl-LPAT + G-diaminopropionic acid
-
Substrates: efficient cleavage
Products: -
?
2-aminobenzoyl-LPNTA-diaminopropionic acid + H2O
2-aminobenzoyl-LPNT + A-diaminopropionic acid
-
Substrates: small amount of cleavage
Products: -
?
4-([4-(dimethylamino)phenyl]-azo)-benzoyl-QALPETGEE-((2-aminoethyl)-amino)naphthalene-1-sulfonic acid + H2O
?
-
Substrates: a catalytically important and conserved binding surface is formed by residues A118, T180 and I182. R197 is also required for catalysis
Products: -
?
4-[[4'-(dimethylamino)phenyl]azo]-benzoyl-Gln-Ala-Leu-Pro-Glu-Thr-Gly-Glu-Glu-5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid + H2O
4-[[4'-(dimethylamino)phenyl]azo]-benzoyl-Gln-Ala-Leu-Pro-Glu-Thr + Gly-Glu-Glu-5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid
-
Substrates: -
Products: -
?
4-[[4'-(dimethylamino)phenyl]azo]-benzoyl-Leu-Pro-Glu-Thr-Gly-5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid + H2O
4-[[4'-(dimethylamino)phenyl]azo]-benzoyl-Leu-Pro-Glu-Thr + Gly-5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid
-
Substrates: -
Products: -
?
5(6)-carboxyfluorescein-6-aminohexanoic acid-LPKTGGRR-NH2 + H2O
?
-
Substrates: -
Products: -
?
A33-LPETG-His6 + H2O
?
-
Substrates: A33 antigen extracellular domain bearing a His6 tag
Products: -
?
Abz-KVENPQTNAGT-Dap(Dnp)-NH2 + GGGGG
Abz-KVENPQTGGGGG + Gly-Dap(DNP)-NH2
-
Substrates: -
Products: -
?
Abz-LPETG-Dap(Dnp) + GGGGG
Abz-LPETGGGGG + G-Dap(Dnp)
-
Substrates: -
Products: -
?
Abz-LPETG-Dap(Dnp) + Gly5
?
-
Substrates: -
Products: -
?
Abz-LPETG-Dap(Dnp) + H2O
?
Abz-LPETG-Dap(Dnp) + H2O
Abz-LPET + G-Dap(Dnp)
Abz-LPETG-Dap(Dnp)-NH2 + GGGGG
?
-
Substrates: -
Products: -
?
Abz-LPETG-Dap(Dnp)-NH2 + GGGGG
Abz-LPETGGGGGG + Gly-Dap(Dnp)-NH2
-
Substrates: -
Products: -
?
Abz-LPETG-Dap(Dnp)-NH2 + Gly5
?
-
Substrates: transpeptidation of LPXTG-containing peptides to the cell-wall precursor mimic NH2-Ala2
Products: -
?
Abz-LPETG-Dap(Dnp)-NH2 + Gly5
Abz-LPETGGGGG-OH + Gly-Dap(Dnp)-NH2
-
Substrates: -
Products: -
?
Abz-LPETG-Dap(Dnp)-NH2 + H2O
?
-
Substrates: -
Products: -
?
Abz-LPETGG-Dap(Dnp)-NH2 + Ala-Ala
Abz-LPETAA + GG-Dap(Dnp)-NH2
Abz-LPETGG-Dap(Dnp)-NH2 + GGGGG
Abz-LPETGGGGGG + Gly-Dap(Dnp)-NH2
-
Substrates: -
Products: -
?
Abz-LPETGK(Dnp)-NH2 + H-Gly3-OH
Abz-LPETGGG-OH + GK(Dnp)-NH2
-
Substrates: transpeptidation activity
Products: -
?
Abz-LPKTGK(Dnp)KK + GGGWW
Abz-LPKTGGGWW + GK(Dnp)KK
-
Substrates: substrate peptide 1 (Abz-LPKTGK(Dnp)KK) and acceptor peptide 2 (GGGWW)
Products: -
?
acetyl-ooocctcttacctcagttacaoooLPKTGGR-NH2 + H-GGGKLALKLALKALKAALKLA-NH2
acetyl-ooocctcttacctcagttacaoooLPKTGGGKLALKLALKALKAALKLA-NH2 + H-GGR-NH2
-
Substrates: -
Products: -
?
agmatine + YALPETGK
(NH2)2-CN-(CH2)4-NH-(CO)-TEPLAY + ?
-
Substrates: transpeptidase reaction. The initially formed acyl-enzyme intermediate undergoes a hydrolysis followed by intra-molecular transpeptidation
Products: -
?
AHLPKTGLR + 5-aminopentan-1-ol
?
-
Substrates: -
Products: -
?
AHLPKTGLR + 6-aminohexyl 4-O-beta-D-galactopyranosyl-beta-D-glucopyranoside
?
-
Substrates: -
Products: -
?
AHLPKTGLR + N-(2-(2-ethoxyethoxy)ethanamine)biotin amide
?
-
Substrates: -
Products: -
?
AHLPKTGLR + N-hexylbiotin amide
?
-
Substrates: -
Products: -
?
AHLPKTGLR-NH2 + triglycine
?
-
Substrates: -
Products: -
?
aminobenzoyl-LPETG-dinitrophenyl ester + Gly-Gly-Gly
aminobenzoyl-LPETGGG + Gly-dinitrophenyl ester
-
Substrates: HPLC results provide direct evidence for the formation of the kinetically competent acyl enzyme intermediate
Products: -
?
Dabcyl-LPETG-EDANS + H2O
Dabcyl-LPET + Gly-EDANS
-
Substrates: -
Products: -
?
Dabcyl-QALPETGEE-Edans + H2O
Dabcyl-QALPET + GEE-Edans
Dabcyl-SFLPKTGM-EDANS + H2O
?
Dabsyl-LLKTGVAS-Edans + H2O
Dabsyl-LLKT + GVAS-Edans
Dabsyl-LPFAGGAG-Edans + H2O
?
Dabsyl-LPFTGGQG-Edans + H2O
Dabsyl-LPFT + GGQG-Edans
Dnp-AQALPETGEE-NH2 + Gly5
?
-
Substrates: -
Products: -
?
Dns-LPKTGGRR + GGGWW
Dns-LPKTGGGWW + GGRR
-
Substrates: dansyl-labeled Dns-LPKTGGRR substrate peptide and acceptor peptide 2 (GGGWW)
Products: -
?
o-aminobenzoyl-Leu-Pro-Glu-Thr-Gly-2,4-dinitrophenyl ester + Gly-Gly-Gly
o-aminobenzoyl-Leu-Pro-Glu-Thr-Gly-Gly-Gly + Gly-2,4-dinitrophenyl ester
-
Substrates: ping-pong mechanism in which a common acyl-enzyme intermediate is formed in transpeptidation and hydrolysis. The nucleophile binding site of the enzyme is specific for diglycine. The S1' and S2' sites of the sortase both prefer a glycine residue, the S1' site is exclusively selective for glycine
Products: -
?
o-aminobenzoyl-Leu-Pro-Glu-Thr-Gly-2,4-dinitrophenyl ester + H2O
o-aminobenzoyl-Leu-Pro-Glu-Thr + Gly-2,4-dinitrophenyl ester
-
Substrates: ping-pong mechanism in which a common acyl-enzyme intermediate is formed in transpeptidation and hydrolysis. The nucleophile binding site of the enzyme is specific for diglycine. The S1' and S2' sites of the sortase both prefer a glycine residue, the S1' site is exclusively selective for glycine
Products: -
?
o-aminobenzoyl-LPETG-2,4-dinitrophenyl + H2O
o-aminobenzoyl-LPETG + 2,4-dinitrophenol
-
Substrates: -
Products: -
?
o-aminobenzoyl-LPETG-2,4-dinitrophenyl ester + H2O
?
-
Substrates: -
Products: -
?
recombinant Helicobacter pylori R1,3-fucosyltransferase + triglycine
?
-
Substrates: -
Products: -
?
recombinant human beta1,4-galactosyltransferase + N-(2-(2-ethoxyethoxy)ethanamine)biotin amide
?
-
Substrates: -
Products: -
?
recombinant human beta1,4-galactosyltransferase + N-hexylbiotin amide
?
-
Substrates: -
Products: -
?
YALPETGK + H2O
YALPET + Gly-Lys
-
Substrates: -
Products: -
?
[4-(4-dimethylaminophenylazo)benzoic acid]-QALPETGEE-[5-[2'-(aminoethyl)amino]-naphthalenesulfonic acid] + H2O
?
-
Substrates: -
Products: -
?
additional information
?
-
Abz-LPETG-Dap(Dnp) + H2O

?
-
Substrates: -
Products: -
?
Abz-LPETG-Dap(Dnp) + H2O
?
-
Substrates: evidence for a reverse protonation catalytic mechanism
Products: -
?
Abz-LPETG-Dap(Dnp) + H2O

Abz-LPET + G-Dap(Dnp)
-
Substrates: cleavage between the threonine and the glycine residues, efficient cleavage
Products: -
?
Abz-LPETG-Dap(Dnp) + H2O
Abz-LPET + G-Dap(Dnp)
-
Substrates: -
Products: -
?
Abz-LPETGG-Dap(Dnp)-NH2 + Ala-Ala

Abz-LPETAA + GG-Dap(Dnp)-NH2
Substrates: transpeptidation of LPXTG-containing peptides to the cell-wall precursor mimic AlaAla
Products: -
?
Abz-LPETGG-Dap(Dnp)-NH2 + Ala-Ala
Abz-LPETAA + GG-Dap(Dnp)-NH2
Substrates: transpeptidation of LPXTG-containing peptides to the cell-wall precursor mimic AlaAla
Products: -
?
Dabcyl-QALPETGEE-Edans + H2O

Dabcyl-QALPET + GEE-Edans
-
Substrates: -
Products: -
?
Dabcyl-QALPETGEE-Edans + H2O
Dabcyl-QALPET + GEE-Edans
-
Substrates: -
Products: -
?
Dabcyl-SFLPKTGM-EDANS + H2O

?
-
Substrates: the substrate mimicks the LPXTG motif of pilus 2a minor ancillary protein
Products: -
?
Dabcyl-SFLPKTGM-EDANS + H2O
?
-
Substrates: the substrate mimicks the LPXTG motif of pilus 2a minor ancillary protein
Products: -
?
Dabsyl-LLKTGVAS-Edans + H2O

Dabsyl-LLKT + GVAS-Edans
Substrates: high activity
Products: -
?
Dabsyl-LLKTGVAS-Edans + H2O
Dabsyl-LLKT + GVAS-Edans
Substrates: high activity
Products: -
?
Dabsyl-LPFAGGAG-Edans + H2O

?
Substrates: low activity
Products: -
?
Dabsyl-LPFAGGAG-Edans + H2O
?
Substrates: low activity
Products: -
?
Dabsyl-LPFTGGQG-Edans + H2O

Dabsyl-LPFT + GGQG-Edans
Substrates: high activity
Products: -
?
Dabsyl-LPFTGGQG-Edans + H2O
Dabsyl-LPFT + GGQG-Edans
Substrates: high activity
Products: -
?
GST-LPETG + G-eGFP

?
-
Substrates: G-eGFP = enhanced green fluorescent protein with a glycine at the N-terminus, protein-protein ligation reaction
Products: -
?
GST-LPETG + G-eGFP
?
-
Substrates: G-eGFP = enhanced green fluorescent protein with a glycine at the N-terminus, protein-protein ligation reaction
Products: -
?
PrtP protein + H2O

?
-
Substrates: -
Products: -
?
PrtP protein + H2O
?
-
Substrates: -
Products: -
?
YbeF protein + H2O

?
-
Substrates: -
Products: -
?
YbeF protein + H2O
?
-
Substrates: -
Products: -
?
YhgE protein + H2O

?
-
Substrates: -
Products: -
?
YhgE protein + H2O
?
-
Substrates: -
Products: -
?
YndF protein + H2O

?
-
Substrates: -
Products: -
?
YndF protein + H2O
?
-
Substrates: -
Products: -
?
YwfG protein + H2O

?
-
Substrates: -
Products: -
?
YwfG protein + H2O
?
-
Substrates: -
Products: -
?
additional information

?
-
-
Substrates: sortase A may be critical in the early stage of inhaltation anthrax
Products: -
?
additional information
?
-
-
Substrates: no cleavage of 2-aminobenzoyl-NPKTG-diaminopropionic acid and 2-aminobenzoyl-LGATG-diaminopropionic acid
Products: -
?
additional information
?
-
-
Substrates: SrtA recognizes the LPXTG-sorting signal through a lock-in-key mechanism
Products: -
?
additional information
?
-
-
Substrates: within the recognition partners of SrtA is a short five amino acid recognition sequence, LPXTG, and through a series of two transthioesterification reactions, the target proteins are covalently linked to a lipid II molecule, using the pendant pentaglycine unit found in lipid II
Products: -
-
additional information
?
-
-
Substrates: two elements of Spa pilin precursor, the pilin motif and the sorting signal, are together sufficient to promote the polymerization of an otherwise secreted protein by a process requiring the function of the sortase A
Products: -
?
additional information
?
-
-
Substrates: two elements of Spa pilin precursor, the pilin motif and the sorting signal, are together sufficient to promote the polymerization of an otherwise secreted protein by a process requiring the function of the sortase A
Products: -
?
additional information
?
-
-
Substrates: sortase localization is facilitated by a positive charge that is necessary for efficient pilus biogenesis
Products: -
?
additional information
?
-
-
Substrates: Lactobacillus acidophilus adheres to Caco-2 cells via sortase A activity
Products: -
-
additional information
?
-
-
Substrates: the two sortase substrates Dabcyl-QALPTTGEE-Edans (LPxTG motif) and Dabcyl-QALPTTDEE-Edans (LPxTD motif) are used for enzyme activity measurements. Substrate QALPTTGEE is more susceptible to SrtA catalysis
Products: -
-
additional information
?
-
-
Substrates: Lactobacillus acidophilus adheres to Caco-2 cells via sortase A activity
Products: -
-
additional information
?
-
-
Substrates: the two sortase substrates Dabcyl-QALPTTGEE-Edans (LPxTG motif) and Dabcyl-QALPTTDEE-Edans (LPxTD motif) are used for enzyme activity measurements. Substrate QALPTTGEE is more susceptible to SrtA catalysis
Products: -
-
additional information
?
-
Substrates: the enzyme is active against the LPXTG motif-based peptide substrates, in-silico analysis of residues involved in substrate binding and specificity, overview. The substrate surface proteins contain conserved N-terminal signal peptide region and C-terminal CWSS (cell wall sorting signal), which consist of LPXTG sorting motif followed by a stretch of hydrophobic region and a positively charged tail for their sortase-mediated decoration at the cell surface. While the signal peptide enables the substrates to export across the cell membrane through general Sec machinery, the C-terminal tail helps them to associate with the lipid membrane after secretion. The membrane-anchored housekeeping sortase cleaves the sorting motif (LPXTG) of substrate between threonine and glycine and then forms an acyl-enzyme intermediate by forming a thioester bond between its active site cysteine and threonine. Modeling of enzyme-peptide substrate interaction
Products: -
-
additional information
?
-
Substrates: the enzyme is active against the LPXTG motif-based peptide substrates, in-silico analysis of residues involved in substrate binding and specificity, overview. The substrate surface proteins contain conserved N-terminal signal peptide region and C-terminal CWSS (cell wall sorting signal), which consist of LPXTG sorting motif followed by a stretch of hydrophobic region and a positively charged tail for their sortase-mediated decoration at the cell surface. While the signal peptide enables the substrates to export across the cell membrane through general Sec machinery, the C-terminal tail helps them to associate with the lipid membrane after secretion. The membrane-anchored housekeeping sortase cleaves the sorting motif (LPXTG) of substrate between threonine and glycine and then forms an acyl-enzyme intermediate by forming a thioester bond between its active site cysteine and threonine. Modeling of enzyme-peptide substrate interaction
Products: -
-
additional information
?
-
-
Substrates: non-gel proteomics is a powerful technique to rapidly identify sortase substrates and to gain insights on potential sorting motifs. LPXTG-containing proteins were identified exclusively in strains having a functional SrtA
Products: -
?
additional information
?
-
-
Substrates: within the recognition partners of SrtA is a short five amino acid recognition sequence, LPXTG, and through a series of two transthioesterification reactions, the target proteins are covalently linked to a lipid II molecule, using the pendant pentaglycine unit found in lipid II
Products: -
-
additional information
?
-
Substrates: the enzyme anchors surface proteins to the bacterial cell wall
Products: -
?
additional information
?
-
-
Substrates: the enzyme anchors surface proteins to the bacterial cell wall
Products: -
?
additional information
?
-
-
Substrates: the enzyme cleaves surface proteins of Staphylococcus aureus at the LPXT-/-G motif
Products: -
?
additional information
?
-
-
Substrates: the enzyme cleaves surface proteins of Staphylococcus aureus at the LPXT-/-G motif
Products: -
?
additional information
?
-
-
Substrates: transpeptidase activity. The enzyme catalyzes a cell wall sorting reaction in which a surface protein with a sorting signal containing a LPXT-/-G motif is cleaved between the Thr and Gly residue. The resulting threonine carboxyl end of the protein is covalently attached to a pentaglycine cross-bridge of peptidoglycan. When a nucleophile is not available, sortase slowly hydrolyzes the LPET-/-G peptide at the same site. Ping-pong mechanism in which a common acyl-enzyme intermediate is formed in transpeptidation and hydrolysis. The nucleophile binding site of the enzyme is specific for diglycine. The S1' and S2' sites of the sortase both prefer a glycine residue, the S1' site is exclusively selective for glycine
Products: -
?
additional information
?
-
-
Substrates: transpeptidase activity: the enzyme catalyzes a cell wall sorting reaction in which a surface protein with a sorting signal containing a LPXT-/-G motif is cleaved between the Thr and Gly residue. The resulting threonine carboxyl end of the protein is covalently attached to a pentaglycine cross-bridge of peptidoglycan. When a nucleophile is not available, sortase slowly hydrolyzes the LPETG peptide at the same site. Ping-pong mechanism in which a common acyl-enzyme intermediate is formed in transpeptidation and hydrolysis. The nucleophile binding site of the enzyme is specific for diglycine
Products: -
?
additional information
?
-
Substrates: the enzyme anchors surface proteins to the bacterial cells wall
Products: -
?
additional information
?
-
-
Substrates: the enzyme anchors surface proteins to the bacterial cells wall
Products: -
?
additional information
?
-
-
Substrates: the enzyme cleaves surface proteins of Staphylococcus aureus at the LPXT-/-G motif, catalyzes surface protein anchoring by means of a transpeptidation reaction that captures cleaved polypeptides as thioester enzyme intermediates
Products: -
?
additional information
?
-
-
Substrates: the enzyme cleaves surface proteins at the LPXTG motif and catalyzes the formation of an amide bond between the carboxyl group of Thr and the amino group of cell-wall crossbridges
Products: -
?
additional information
?
-
-
Substrates: gram-positive pathogenic bacteria display proteins on their surface that play important roles during infection. In Staphylococcus aureus theses surface proteins are anchored to the cell wall by two sortase, sortase A and sortaseB that recognize specific surface protein sorting signals. Sortase A is an essential virulence factor for establishment of septic arthritis
Products: -
?
additional information
?
-
-
Substrates: the transpeptidase required for cell wall protein anchoring and virulence in Staphylococcus aureus
Products: -
?
additional information
?
-
-
Substrates: primary role of the SrtA isoform in Staphylococcus aureus adhesion and host colonization
Products: -
?
additional information
?
-
-
Substrates: sortase A plays a role in the establishment of infections
Products: -
?
additional information
?
-
-
Substrates: sortase can transfer peptide substrates to oligosaccharides appended with a 6-deoxy-6-aminohexose moiety in a selective manner as that of an oligoglycine sequence
Products: -
?
additional information
?
-
-
Substrates: SrtA cleaves proteins at LPXTG-motif between threonine and glycine, and subsequently transfers the acyl-fragment to a N-terminal oligoglycine
Products: -
?
additional information
?
-
-
Substrates: the enzyme cleaves the LPXTG sequence at the amide bond between the threonine and the glycine to form an acyl-enzyme complex. Nucleophilic attack by the amino group of the tri-glycine on the intermediate results in the formation of an LPXT-GGG bond and the liberation of the free enzyme
Products: -
?
additional information
?
-
-
Substrates: SrtA recognizes LPXTG near the C-terminus of a target protein. The Cys184 of SrtA performs a nucleophilic attack at the peptide bond between T and G in LPXTG, resulting in a thioester intermediate with the carboxyl group of the C-terminal T linked to Cys184. This reactive intermediate reacts with the cross-bridge N-terminus of a cell-wall proteoglycan to anchor the target protein to the cell-wall peptidoglycan. SrtA accepts various peptide/protein substrates, so long as they bear the sorting signal LPXTG, and a range of amino nucleophiles
Products: -
?
additional information
?
-
-
Substrates: sortase-mediated cyclization of histatin-1 (GG-histatin 1-LPETGG) provides a yield of more than 90%
Products: -
?
additional information
?
-
-
Substrates: sortase A optimal cleavage site is LPETGG
Products: -
?
additional information
?
-
-
Substrates: truncated SrtADELTAN40 also catalyzes in vitro transpeptidation reaction
Products: -
?
additional information
?
-
-
Substrates: no activity with Dabcyl-KGIIPKTGGK-Edans, Dabcyl-KKVTIPQTGGIGT-Edans and Dabcyl-SFIPKTGM-Edans
Products: -
?
additional information
?
-
-
Substrates: sortase A also mediates transpeptidation reaction of indolicidin-derived peptides
Products: -
?
additional information
?
-
-
Substrates: sortase A mediates either head to tail cyclization or oligomerization and then head to tail cyclization of peptides (e.g. GGVTSAPDTLPKTGGS) and glycopeptides (e.g. MUC1 glycopeptide), depending on the peptide length, to produce 15-mer or higher cyclic peptides and glycopeptides
Products: -
?
additional information
?
-
-
Substrates: the bacterial transpeptidase sortase A catalyzes the chemoselective ligation of peptides and proteins. During catalysis sortase A cleaves the conserved Leu-Pro-X-Thr-Gly sorting motif at the Thr residue under concomitant thioester formation at active site Cys184
Products: -
?
additional information
?
-
-
Substrates: Surface proteins destined for cell wall anchoring contain a LPXTG sequence located in their C-terminus which serves as a substrate recognition motif for SrtA
Products: -
?
additional information
?
-
-
Substrates: the enzyme recognizes a 5-residue sequence motif, LPXTG, and cleaves the peptide bond between the Thr and Gly residues, forming an acyl enzyme intermediate between a cysteine at the active site of SrtA and the carboxylate at the truncated C-terminus of the substrate
Products: -
?
additional information
?
-
-
Substrates: the enzyme is highly selective and does not require any cofactors for the catalysis of protein ligation, but it is unable to access the recognition site within the highly structured regions of folded substrates. Ligation of purified glutathione-S-transferase and green fluorescence protein by recombinant circular enzyme
Products: -
?
additional information
?
-
-
Substrates: semienzymatic cyclization of disulfide-rich peptides using sortase A, including the cyclotide kalata B1, alpha-conotoxin Vc1.1, and sunflower trypsin inhibitor 1, without the need for a thioester linker and using Fmoc chemistry, NMR spectral structure analysis, overview
Products: -
?
additional information
?
-
-
Substrates: in the bacterial cell membrane, SrtA cleaves the Thr-Gly scissile bond of the LPXTG-containing protein and forms a new amide bond with the nucleophilic amino group of the Gly5 moiety of lipid II
Products: -
-
additional information
?
-
-
Substrates: SrtA catalyzed surface protein anchoring mechanism includes recognition of target MSCRAMMs, transthioesterification, and transpeptidation, overview
Products: -
-
additional information
?
-
-
Substrates: within the recognition partners of SrtA is a short five amino acid recognition sequence, LPXTG, and through a series of two transthioesterification reactions, the target proteins are covalently linked to a lipid II molecule, using the pendant pentaglycine unit found in lipid II
Products: -
-
additional information
?
-
Substrates: interaction sortase A from Staphylococcus aureus with nucleic acids, exogenously expressed engineered sortase A binds oligonucleotides in vitro and independently of its canonical transpeptidase activity. When incubated with mammalian cells, engineered sortase A further mediates oligonucleotide labeling of the cell surface, where sortase A attaches itself and is part of the labeled moiety. mgSrtA-Mediated cell labeling shows nucleotide selectivity. Among the four DNA oligonucleotides (FITC- or biotin- or TAMRA-modified 4A (AAAA), 4T (TTTT), 4C (TTTT), and 4G (GGGG) DNA oligonucleotides), the 4G oligonucleotide produce the highest MFI, indicating that mgSrtA-mediated oligonucleotide cell labeling exhibits a preference for guanine, this preference is independent of modification. Quantification of K562 cells labeled with Cy5-modified RNA oligonucleotide and with Cy5-modified RNA oligonucleotides at different concentrations. mgSrtA mediates the labeling of the mammalian cell surfaces with various forms of nucleic acids, overview
Products: -
-
additional information
?
-
-
Substrates: the recombinant detagged enzyme catalyzes the ligation reaction with an engineered Rad50 segment 3 OaAEP1 mutant, overview
Products: -
-
additional information
?
-
-
Substrates: Staphylococcus aureus SrtA can ligate nucleophilic peptides containing an N-terminal oligoglycine onto proteins with a C-terminal LPXTG SrtA recognition motif. The ligation reaction is reversible. Long reaction times lower labeling efficiency through the accumulation of the irreversible hydrolysis side product
Products: -
-
additional information
?
-
Substrates: enzyme SrtA is able to recognize and process a variety of exogenously added synthetic SrtA substrates, including K(FITC)LPMTG-amide and K(FITC)-K-vancomycin-LPMTGamide. These synthetic substrates are covalently incorporated into the bacterial peptidoglycan (PG) of Staphylococcus aureus with varying efficiencies. Analysis of the effect of the lipid II inhibiting antibiotic bacitracin on the incorporation of native and synthetic SrtA substrates, overview. Besides the endogenous CWA proteins, SrtA also incorporated exogenously added synthetic SrtA substrates equipped with the SrtA recognition motif. Only little, if any, competition occur with natural substrates. While incorporation of the natural substrates peaks in the logarithmic growth phase, incorporation of synthetic substrates peaks in the stationary phase. Binding of vancomycin to D-Ala-D-Ala within the sortase substrate (K(FITC)-K-vancomycin-LPMTGamide) increases transpeptidation by SrtA. Mechanism, overview
Products: -
-
additional information
?
-
-
Substrates: structure-activity relationship of the stem peptide in sortase A mediated ligation using substrate GGGK(tmr) and tripeptide and tetrapeptide analogues of Staphylococcus aureus peptidoglycan (PG), fluorescence analysis, mechanism, overview. Synthesis of a penta-stem peptide with a TAMRA-modified N-terminus and varied the glycine bridge length as 5 (tmrPEgly5), 3 (tmrPEgly3), or 1 (tmrPEgly1) glycine(s)
Products: -
-
additional information
?
-
-
Substrates: the transpeptidation mechanism is initiated by the nucleophilic attack of the thiol group of C184 of sortase A to the peptide bond between the threonine and the glycine of the LPETG motif, yielding a covalent thioacyl intermediate and the release of the terminal glycine and additional C-terminal sequences if present. The thioacyl can then be resolved by the nucleophilic attack of an oligoglycine stretch (such as G5-toxin), resulting in the formation of a new peptide bond between the threonine and the incoming glycine (LPETG5-toxin). Method of synthesis of antibody-conjugates, detailed overview
Products: -
-
additional information
?
-
Substrates: the enzyme conjugates interleukin-2 in vitro with fatty acids
Products: -
-
additional information
?
-
-
Substrates: truncated SrtADELTAN40 also catalyzes in vitro transpeptidation reaction
Products: -
?
additional information
?
-
-
Substrates: no activity with Dabcyl-KGIIPKTGGK-Edans, Dabcyl-KKVTIPQTGGIGT-Edans and Dabcyl-SFIPKTGM-Edans
Products: -
?
additional information
?
-
-
Substrates: the enzyme is highly selective and does not require any cofactors for the catalysis of protein ligation, but it is unable to access the recognition site within the highly structured regions of folded substrates. Ligation of purified glutathione-S-transferase and green fluorescence protein by recombinant circular enzyme
Products: -
?
additional information
?
-
Substrates: interaction sortase A from Staphylococcus aureus with nucleic acids, exogenously expressed engineered sortase A binds oligonucleotides in vitro and independently of its canonical transpeptidase activity. When incubated with mammalian cells, engineered sortase A further mediates oligonucleotide labeling of the cell surface, where sortase A attaches itself and is part of the labeled moiety. mgSrtA-Mediated cell labeling shows nucleotide selectivity. Among the four DNA oligonucleotides (FITC- or biotin- or TAMRA-modified 4A (AAAA), 4T (TTTT), 4C (TTTT), and 4G (GGGG) DNA oligonucleotides), the 4G oligonucleotide produce the highest MFI, indicating that mgSrtA-mediated oligonucleotide cell labeling exhibits a preference for guanine, this preference is independent of modification. Quantification of K562 cells labeled with Cy5-modified RNA oligonucleotide and with Cy5-modified RNA oligonucleotides at different concentrations. mgSrtA mediates the labeling of the mammalian cell surfaces with various forms of nucleic acids, overview
Products: -
-
additional information
?
-
Substrates: enzyme SrtA is able to recognize and process a variety of exogenously added synthetic SrtA substrates, including K(FITC)LPMTG-amide and K(FITC)-K-vancomycin-LPMTGamide. These synthetic substrates are covalently incorporated into the bacterial peptidoglycan (PG) of Staphylococcus aureus with varying efficiencies. Analysis of the effect of the lipid II inhibiting antibiotic bacitracin on the incorporation of native and synthetic SrtA substrates, overview. Besides the endogenous CWA proteins, SrtA also incorporated exogenously added synthetic SrtA substrates equipped with the SrtA recognition motif. Only little, if any, competition occur with natural substrates. While incorporation of the natural substrates peaks in the logarithmic growth phase, incorporation of synthetic substrates peaks in the stationary phase. Binding of vancomycin to D-Ala-D-Ala within the sortase substrate (K(FITC)-K-vancomycin-LPMTGamide) increases transpeptidation by SrtA. Mechanism, overview
Products: -
-
additional information
?
-
Substrates: the enzyme conjugates interleukin-2 in vitro with fatty acids
Products: -
-
additional information
?
-
-
Substrates: sortase A plays a role in the establishment of infections
Products: -
?
additional information
?
-
Substrates: interaction sortase A from Staphylococcus aureus with nucleic acids, exogenously expressed engineered sortase A binds oligonucleotides in vitro and independently of its canonical transpeptidase activity. When incubated with mammalian cells, engineered sortase A further mediates oligonucleotide labeling of the cell surface, where sortase A attaches itself and is part of the labeled moiety. mgSrtA-Mediated cell labeling shows nucleotide selectivity. Among the four DNA oligonucleotides (FITC- or biotin- or TAMRA-modified 4A (AAAA), 4T (TTTT), 4C (TTTT), and 4G (GGGG) DNA oligonucleotides), the 4G oligonucleotide produce the highest MFI, indicating that mgSrtA-mediated oligonucleotide cell labeling exhibits a preference for guanine, this preference is independent of modification. Quantification of K562 cells labeled with Cy5-modified RNA oligonucleotide and with Cy5-modified RNA oligonucleotides at different concentrations. mgSrtA mediates the labeling of the mammalian cell surfaces with various forms of nucleic acids, overview
Products: -
-
additional information
?
-
Substrates: enzyme SrtA is able to recognize and process a variety of exogenously added synthetic SrtA substrates, including K(FITC)LPMTG-amide and K(FITC)-K-vancomycin-LPMTGamide. These synthetic substrates are covalently incorporated into the bacterial peptidoglycan (PG) of Staphylococcus aureus with varying efficiencies. Analysis of the effect of the lipid II inhibiting antibiotic bacitracin on the incorporation of native and synthetic SrtA substrates, overview. Besides the endogenous CWA proteins, SrtA also incorporated exogenously added synthetic SrtA substrates equipped with the SrtA recognition motif. Only little, if any, competition occur with natural substrates. While incorporation of the natural substrates peaks in the logarithmic growth phase, incorporation of synthetic substrates peaks in the stationary phase. Binding of vancomycin to D-Ala-D-Ala within the sortase substrate (K(FITC)-K-vancomycin-LPMTGamide) increases transpeptidation by SrtA. Mechanism, overview
Products: -
-
additional information
?
-
Substrates: the enzyme conjugates interleukin-2 in vitro with fatty acids
Products: -
-
additional information
?
-
-
Substrates: SrtA sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine
Products: -
?
additional information
?
-
-
Substrates: within the recognition partners of SrtA is a short five amino acid recognition sequence, LPXTG, and through a series of two transthioesterification reactions, the target proteins are covalently linked to a lipid II molecule, using the pendant pentaglycine unit found in lipid II
Products: -
-
additional information
?
-
-
Substrates: in addition to its role in processing LPXTG containing adhesins, sortase A has the function of contributing to transcriptional regulation of adhesin gene expression
Products: -
?
additional information
?
-
-
Substrates: within the recognition partners of SrtA is a short five amino acid recognition sequence, LPXTG, and through a series of two transthioesterification reactions, the target proteins are covalently linked to a lipid II molecule, using the pendant pentaglycine unit found in lipid II
Products: -
-
additional information
?
-
Substrates: SrtA enzyme activities are measured through a fluorophotometric method using synthetic peptide substrate containing the LPETG motif
Products: -
-
additional information
?
-
Substrates: SrtA enzyme activities are measured through a fluorophotometric method using synthetic peptide substrate containing the LPETG motif
Products: -
-
additional information
?
-
Substrates: SrtA enzyme activities are measured through a fluorophotometric method using synthetic peptide substrate containing the LPETG motif
Products: -
-
additional information
?
-
-
Substrates: role of srtA in adherence in vitro is dependent on capsule expression, the role of SrtA in adherence to human cells only being apparent in the absence of the pneumococcal capsule
Products: -
?
additional information
?
-
-
Substrates: SrtA is dispensable for pilus assembly and localization to the cell wall
Products: -
?
additional information
?
-
-
Substrates: within the recognition partners of SrtA is a short five amino acid recognition sequence, LPXTG, and through a series of two transthioesterification reactions, the target proteins are covalently linked to a lipid II molecule, using the pendant pentaglycine unit found in lipid II
Products: -
-
additional information
?
-
-
Substrates: within the recognition partners of SrtA is a short five amino acid recognition sequence, LPXTG, and through a series of two transthioesterification reactions, the target proteins are covalently linked to a lipid II molecule, using the pendant pentaglycine unit found in lipid II
Products: -
-
additional information
?
-
-
Substrates: SrtA contributes to antiopsonization in Streptococci. SrtA anchors surface adhesins as well as some proteins that function as antiopsonic molecules as a means of evading the human immune system. SrtA of Streptococcus sanguinis plays important roles in bacterial colonization
Products: -
?
additional information
?
-
-
Substrates: SrtA is involved in the virulence manifestation of streptococcal toxic shock syndrome
Products: -
?
additional information
?
-
Substrates: sortase A anchors the following proteins in the cell wall of Streptococcus uberis strain 0140J: putative fructan beta-fructosidase precursor, putative lactoferrin binding protein, putative collagen-like surface anchored protein, putative C5a peptidase precursor, and putative zinc-carboxypeptidase. Alternate cell wall anchoring motifs are either LPXTXD/E or LPXXXD
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
((2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one)
-
((2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one)
-
((2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one)(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(1-methyl-1H-indol-3-yl)[3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(1E)-N'-[(1E)-(4-[(E)-[(diaminomethylene)hydrazono]methyl]phenyl)methylene]ethanehydrazonamide
-
-
(1H-indol-3-yl)[4-(1H-indol-3-yl)-1H-imidazol-2-yl]methanone
-
-
(2-(trimethylammonium)ethyl)methanethiosulfonate
-
inhibition at 5 mM, inhibition is relieved by supplementing the reaction with 10 mM dithiothreitol
(2-amino-6-chloro-1H-indol-3-yl)(morpholin-4-yl)methanone
(2-methyl-1H-indol-3-yl)(oxo)acetic acid
-
-
(2-sulfonatoethyl)methanethiosulfonate
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one (2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
-
(2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
(2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
(2E)-2,3-bis(4-methoxyphenyl)acrylamide
-
IC50: 0.476 mM
(2E)-2,3-bis(4-methoxyphenyl)acrylonitrile
-
IC50: 0.187 mM
(2E)-2-(2-furoyl)-3-[(methyl[4-[(5-nitropyridin-2-yl)oxy]phenyl]oxido-l4-sulfanylidene)amino]acrylonitrile
-
-
(2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(2-furyl)-N-[3-(hydroxymethyl)-4-morpholin-4-ylphenyl]acrylamide
-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
(2E)-3-[(methyl[4-[(5-nitropyridin-2-yl)oxy]phenyl]oxido-l4-sulfanylidene)amino]-2-(2-thienylcarbonyl)acrylonitrile
-
-
(2E)-4-([4-[(2-hydroxybenzoyl)amino]phenyl]amino)-4-oxobut-2-enoic acid
-
-
(2E)-N-(3-formyl-4-morpholin-4-ylphenyl)-3-(2-furyl)acrylamide
-
-
(2E)-N-(3-formyl-4-morpholin-4-ylphenyl)-3-(2-thienyl)acrylamide
-
-
(2E)-N-[3-(hydroxymethyl)-4-morpholin-4-ylphenyl]-3-(2-thienyl)acrylamide
-
-
(2S)-2-[[(2R)-2-[[(2R)-2-([(2R)-1-[(2S)-2-[[(3S,4S)-3-acetamido-4-hydroxypentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino)-3-(4-hydroxyphenyl)propanoyl](methyl)amino]-3-phenylpropanoyl]amino]propanoic acid
(2Z)-2,3-bis(4-methoxyphenyl)acrylonitrile
-
IC50: 0.0279mM
(2Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
-
IC50: 0.009244 mM
(2Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl)prop-2-enenitrile
-
-
(2Z)-3-(2-methoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
-
IC50: 0.0362 mM
(2Z)-3-(3,4-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
-
IC50: 0.02296 mM
(2Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
-
IC50: 0.025463 mM
(2Z)-3-(3-methoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
-
IC50: 0.0174 mM
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone
(4E)-5-methyl-4-[[(4-nitrophenyl)amino]methylidene]-2-phenyl-2,4-dihydro-3H-pyrazole-3-thione
-
-
(5-bromo-1-methyl-1H-indol-3-yl)[3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(5-bromo-1-methyl-1H-indol-3-yl)[3-(5-chloro-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(5-bromo-1-methyl-1H-indol-3-yl)[3-(5-fluoro-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(5-bromo-1-methyl-1H-indol-3-yl)[3-(5-methoxy-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(5-fluoro-1-methyl-1H-indol-3-yl)[3-(5-fluoro-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(5-fluoro-1-methyl-1H-indol-3-yl)[3-(5-methoxy-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(5-methoxy-1-methyl-1H-indol-3-yl)[3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(5-methoxy-1-methyl-1H-indol-3-yl)[3-(5-methoxy-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl]methanone
-
-
(5R)-3,5-bis(6-bromo-1H-indol-3-yl)-5,6-dihydropyrazin-2(1H)-one
-
IC50: 68.98 mg/L
(5Z)-3-(2,4-dimethylphenyl)-5-(3-nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(3-chlorophenyl)-5-(4-methyl-3-nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-ethyl-5-(2-nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-(2,4-dimethylphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-(3-chlorophenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-(3-methylphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-(4-nitrophenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-phenyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3-bromo-4-hydroxy-5-nitrobenzylidene)-3-(2,4-dimethylphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3-chlorobenzylidene)-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-benzylidene-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-benzylidene-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-benzylidene-3-propyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(6-hydroxy-1H-indol-3-yl)(oxo)acetic acid
-
-
(6-methoxy-1H-indol-3-yl)(oxo)acetic acid
-
-
(6-methyl-1H-inden-3-yl)[4-(6-methyl-1H-indol-3-yl)-1H-imidazol-2-yl]methanone
-
IC50: 15.67 mg/Ll
(6R)-3,6-bis(6-bromo-1H-indol-3-yl)-5,6-dihydropyrazin-2(1H)-one
-
IC50: 86.34 mg/L
(6R)-6-(6-bromo-1H-indol-3-yl)-3-(1H-indol-3-yl)-5,6-dihydropyrazin-2(1H)-one
-
IC50: 34.04 mg/L
(Z)-2-(4-(1-cyano-2-(2,4,6-methylphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(2,4,6-methylphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(2,5-methoxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(2,5-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(2-carboxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(2-carboxyphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(3,4-benzyloxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(3,4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(3,4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(3,4-methylphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(3,4-methylphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-(trifluoromethyl)phenyl)vinyl)phenyl)-N-isobutylbenzofuran-3-carboxamide
-
-
(Z)-2-(4-(1-cyano-2-(4-benzyloxyphenyl)vinyl)phenyl)-Nisobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-bromophenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-bromophenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-bromophenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-chlorophenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-chlorophenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-chlorophenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-ethylphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-ethylphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-fluorophenyl)vinyl)phenyl)-N-isobutylbenzofuran-3-carboxamide
-
-
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-(4-methylphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano-2-phenylvinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
-
-
(Z)-2-(4-(1-cyano2-phenylvinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
-
-
(Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile
-
potential of this inhibitor for the treatment of Staphylococcus aureus infections
1,2-bis(5-hydroxy-1H-indol-3-yl)ethane-1,2-dione
-
-
1-(2,4-dihydroxy-6-methoxyphenyl)ethan-1-one
-
1-(3,4-dichlorophenyl)-3-(dimethylamino)propan-1-one
-
-
1-(3-methoxyphenyl)-2,3,4,9-tetrahydro-1H-beta-carboline
-
-
1-(4-bromophenyl)-3-(3-methylpiperidin-1-yl)propan-1-one
-
-
1-(4-chlorophenyl)-3-morpholin-4-ylpropan-1-one
-
-
1-(4-fluorophenyl)-3-morpholin-4-ylpropan-1-one
-
-
1-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-beta-carboline
-
-
1-(4-methylphenyl)-3-morpholin-4-ylpropan-1-one
-
-
1-(naphthalen-2-yl)-2,3,4,9-tetrahydro-1H-beta-carboline
-
-
1-pentyl-2,3,4,9-tetrahydro-1H-beta-carboline
-
-
1-phenyl-2,3,4,9-tetrahydro-1H-beta-carbolin-7-ol
-
-
1-phenyl-2,3,4,9-tetrahydro-1H-beta-carboline
-
-
1-phenyl-4,9-dihydro-3H-beta-carboline
-
-
1-[4-(2-aminopyrimidin-4-yl)phenyl]-3-(4-chlorophenyl)urea
-
-
1H-indol-3-yl(oxo)acetic acid
-
-
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone
2,3,4,9-tetrahydro-1H-beta-carboline-1-carboxylic acid
-
-
2,5-dihydroxy-6-(propan-2-yl)cyclohepta-2,4,6-trien-1-one
-
2-(((5-amino-1,3,4-thiadiazol-2-yl)thio)methyl)benzonitrile
-
-
2-((3-nitrobenzyl)thio)-5-(piperazin-1-yl)-1,3,4-thiadiazole
-
-
2-((4-nitrobenzyl)thio)-5-(piperazin-1-yl)-1,3,4-thiadiazole
-
-
2-(1-oxoisoindolin-2-yl)acetic acid
-
-
2-(1H-indol-3-yl)-2-oxo-N-phenylacetamide
-
-
2-(2-amino-3-chlorobenzamido)benzoic acid
2-(2-methyl-1H-indol-3-yl)-2-oxo-N-phenylacetamide
-
-
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
-
2-(3,5-dichlorophenyl)-4-(ethylsulfanyl)-5-sulfanylpyridazin-3(2H)-one
-
-
2-(3,5-dichlorophenyl)-5-ethoxy-4-sulfanylpyridazin-3(2H)-one
-
-
2-(3-bromophenyl)-4,5-dichloropyridazin-3(2H)-one
-
-
2-(3-bromophenyl)-4-(ethylsulfanyl)-5-sulfanylpyridazin-3(2H)-one
-
-
2-(3-bromophenyl)-4-chloro-5-ethoxypyridazin-3(2H)-one
-
-
2-(3-bromophenyl)-5-chloro-4-ethoxypyridazin-3(2H)-one
-
-
2-(3-bromophenyl)-5-chloro-4-methoxypyridazin-3(2H)-one
-
-
2-(3-chlorophenyl)-4-methoxy-5-sulfanylpyridazin-3(2H)-one
-
-
2-(3-oxo-1,2-benzothiazol-2(3H)-yl)-N-(tricyclo[3.3.1.13,7]dec-1-yl)acetamide
-
-
2-(4-(1-cyanovinyl)phenyl)-N-isobutylbenzofuran-3-carboxamide
-
-
2-(4-nitrophenyl)-4,5-dichloropyridazin-3-one
-
-
2-(4-[2-[4-(benzyloxy)phenyl]-1-cyanoethyl]phenyl)-N-(2-methylpropyl)-1-benzofuran-3-carboxamide
-
-
2-(6-hydroxy-1H-indol-3-yl)-2-oxo-N-phenylacetamide
-
-
2-(6-methoxy-1H-indol-3-yl)-2-oxo-N-phenylacetamide
-
-
2-(morpholin-4-yl)-5-[[(2E)-3-(thiophen-2-yl)prop-2-enoyl]amino]benzoic acid
-
-
2-bromo-5-((3-nitrobenzyl)thio)-1,3,4-thiadiazole
-
-
2-cyclohexyl-4-(ethylsulfanyl)-5-sulfanylpyridazin-3(2H)-one
-
-
2-ethyl-4-hydroxy-5-(methylsulfanyl)pyridazin-3(2H)-one
-
-
2-hydroxy-1-(5-hydroxy-1H-indol-3-yl)ethanone
-
-
2-hydroxy-5-[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]-4-(propan-2-yl)cyclohepta-2,4,6-trien-1-one
-
2-hydroxy-N-[4-[([[(4-methylphenyl)sulfonyl]amino]carbonyl)amino]phenyl]benzamide
-
-
2-morpholin-4-yl-5-[[(2E)-3-(2-thienyl)prop-2-enoyl]amino]benzamide
-
-
2-phenyl-4,5-dichloro-pyridazin-3-one
-
-
2-[(1H-1,2,4-triazol-3-yl)sulfanyl]-4-(trifluoromethyl)pyrimidine
-
-
2-[(2-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
2-[(3-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
2-[(4-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
2-[4-(1-cyano-2-phenylethyl)phenyl]-N-(2-methylpropyl)-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-dihydroxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
2-[4-[(Z)-1-cyano-2-(3,4-diphenoxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
2-[4-[(Z)-1-cyano-2-phenylethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
2-[4-[1-cyano-2-(3,4-dihydroxyphenyl)ethyl]phenyl]-N-(2-methylpropyl)-1-benzofuran-3-carboxamide
-
-
2-[4-[1-cyano-2-(4-hydroxyphenyl)ethyl]phenyl]-N-(2-methylpropyl)-1-benzofuran-3-carboxamide
-
-
3',3''-dihydroxy-(-)-matairesinol
3,3,3-trifluoro-1-(phenylsulfonyl)-1-propene
-
IC50: 0.19 mM, irreversible
3,4-bis[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
-
3,5-bis[[2-(4-nitrophenyl)-2-oxoethyl]thio]isothiazole-4-carbonitrile
-
-
3-(2-aminoethyl)-1H-indol-5-ol
-
-
3-(3-oxo-1,2-benzothiazol-2(3H)-yl)propanoic acid
-
-
3-(dimethylamino)-1-(2-thienyl)propan-1-one
-
-
3-(dimethylamino)-1-(3-nitrophenyl)propan-1-one
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-1-chloro-1,3,5-trideoxy-D-glycero-pent-2-ulose
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-3,5-dideoxy-1-thio-D-glycero-pent-2-ulose
3-anilino-1-(3-nitrophenyl)propan-1-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[(4-methoxyphenyl)[(pyridin-2-yl)amino]methyl]-4H-pyran-4-one
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino](thiophen-3-yl)methyl]-4H-pyran-4-one
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino][4-(trifluoromethyl)phenyl]methyl]-4H-pyran-4-one
3-[(1H-indol-3-yl)methyl]-2H-1-benzopyran-2,4(3H)-dione
4,5-dichloro-2-(3,5-dichlorophenyl)pyridazin-3(2H)-one
-
-
4,5-dichloro-2-(3-fluorophenyl)pyridazin-3(2H)-one
-
-
4,5-dichloro-2-(3-methylphenyl)pyridazin-3(2H)-one
-
-
4,5-dichloro-2-cyclohexylpyridazin-3(2H)-one
-
-
4-(((5-amino-1,3,4-thiadiazol-2-yl)thio)methyl)benzonitrile
-
-
4-(5-((3-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)morpho-line
-
-
4-(5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)morpho-line
-
-
4-(benzyloxy)-5-hydroxy-2-phenylpyridazin-3(2H)-one
-
-
4-(ethylsulfanyl)-2-(3-fluorophenyl)-5-sulfanylpyridazin-3(2H)-one
-
-
4-(ethylsulfanyl)-2-(3-methylphenyl)-5-sulfanylpyridazin-3(2H)-one
-
-
4-(ethylsulfanyl)-2-(4-nitrophenyl)-5-sulfanylpyridazin-3(2H)-one
-
-
4-(ethylsulfanyl)-2-phenyl-5-sulfanylpyridazin-3(2H)-one
-
-
4-(ethylsulfanyl)-5-hydroxy-2-phenylpyridazin-3(2H)-one
-
-
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
4-chloro-2-(3,5-dichlorophenyl)-5-ethoxypyridazin-3(2H)-one
-
-
4-chloro-2-cyclohexyl-5-ethoxypyridazin-3(2H)-one
-
-
4-chloro-5-(methylsulfanyl)-2-phenylpyridazin-3(2H)-one
-
-
4-chloro-5-ethoxy-2-(3-fluorophenyl)pyridazin-3(2H)-one
-
-
4-chloro-5-ethoxy-2-(3-methylphenyl)pyridazin-3(2H)-one
-
-
4-chloro-5-ethoxy-2-(4-nitrophenyl)pyridazin-3(2H)-one
-
-
4-chloro-5-ethoxy-2-phenylpyridazin-3-one
-
-
4-ethoxy-2-phenyl-5-sulfanylpyridazin-3(2H)-one
-
-
4-ethoxy-5-(2-pyridyldithio)-2-phenylpyridazin-3-one
-
-
4-ethoxy-5-(methyldithio)-2-phenylpyridazin-3-one
-
-
4-ethoxy-5-mercapto-2-phenylpyridazin-3-one
-
-
4-hydroxy-5-(methylsulfanyl)-2-phenylpyridazin-3(2H)-one
-
-
4-hydroxymercuribenzoate
-
-
5-((3-nitrobenzyl)thio)-1,3,4-thiadiazol-2-amine
-
-
5-((3-nitrobenzyl)thio)-N-(pyridin-3-yl)-1,3,4-thiadiazol-2-amine
-
-
5-((3-nitrophenethyl)thio)-1,3,4-thiadiazol-2-amine
-
-
5-((4-fluorobenzyl)thio)-1,3,4-thiadiazol-2-amine
-
-
5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-amine
-
-
5-((4-nitrobenzyl)thio)-N-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine
-
-
5-((4-nitrophenyl)thio)-1,3,4-thiadiazol-2-amine
-
-
5-((C4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-amine
-
2NapLPRDA, 77.1% inhibition at 0.2 mM
-
5-((naphthalen-2-ylmethyl)thio)-1,3,4-thiadiazol-2-amine
-
-
-
5-(2-fluoro-5-methoxyphenyl)-4-(hydroxymethyl)-1-methylproline
5-(5'-acetyl-7-fluoro-6'-methylspiro[indeno[1,2-b]quinoxaline-11,4' -[1,3]dithiin]-2'-ylidene)pyrimidine-2,4,6(1H,3H,5H)trione
-
-
5-(5'-acetyl-7-fluoro-6'-methylspiro[indeno[1,2-b]quinoxaline-11,4'-[1,3]dithiin]-2'-ylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
-
5-(phenylthio)-1,3,4-thiadiazol-2-amine
-
-
5-chloro-2-(3,5-dichlorophenyl)-4-ethoxypyridazin-3(2H)-one
-
-
5-chloro-2-(3,5-dichlorophenyl)-4-methoxypyridazin-3(2H)-one
-
-
5-chloro-2-(3-fluorophenyl)-4-methoxypyridazin-3(2H)-one
-
-
5-chloro-2-(methanesulfonyl)-N-(3-phenoxyphenyl)pyrimidine-4-carboxamide
5-chloro-2-(methanesulfonyl)-N-[2-oxo-3-(3-phenoxyphenyl)propyl]pyrimidine-4-carboxamide
5-chloro-2-cyclohexyl-4-ethoxypyridazin-3(2H)-one
-
-
5-chloro-2-cyclohexyl-4-methoxypyridazin-3(2H)-one
-
-
5-chloro-4-ethoxy-2-(3-fluorophenyl)pyridazin-3(2H)-one
-
-
5-chloro-4-ethoxy-2-(3-methylphenyl)pyridazin-3(2H)-one
-
-
5-chloro-4-ethoxy-2-(4-nitrophenyl)pyridazin-3(2H)-one
-
-
5-chloro-4-ethoxy-2-phenylpyridazin-3-one
-
-
5-chloro-4-methoxy-2-(3-methylphenyl)pyridazin-3(2H)-one
-
-
5-chloro-4-methoxy-2-phenylpyridazin-3(2H)-one
-
-
5-ethoxy-2-(3-fluorophenyl)-4-sulfanylpyridazin-3(2H)-one
-
-
5-ethoxy-2-(3-methylphenyl)-4-sulfanylpyridazin-3(2H)-one
-
-
5-ethoxy-2-phenyl-4-sulfanylpyridazin-3(2H)-one
-
-
5-hydroxy-1H-indole-3-carbaldehyde
-
-
5-hydroxy-4-methoxy-2-phenylpyridazin-3(2H)-one
-
-
5-methoxy-2-phenyl-4-sulfanylpyridazin-3(2H)-one
-
-
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione
5-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]-1,3,4-thiadiazol-2-amine
-
-
5-[[(2E)-3-(2-furyl)prop-2-enoyl]amino]-2-morpholin-4-ylbenzoic acid
-
-
6-amino-7'-fluoro-2-(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)spiro[[1,3] dithiine-4,11'7-indeno[1,2-b]quinoxaline]-5-carbonitrile
-
-
6-amino-7'-fluoro-2-(2-oxocycloheptylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
-
-
6-amino-7'-fluoro-2-(2-oxocyclohexylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
-
-
6-amino-7'-fluoro-2-(3-methyl-5-oxo-1-phenyl-1H-pyrazol-4(5H)ylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
-
-
6-amino-7'-fluoro-2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)spiro[[1,3] dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
-
-
6-amino-7'-fluoro-2-(5-methyl-2-oxocyclohexylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
-
-
6-hydroxy-2,3,4,9-tetrahydro-1H-beta-carbolin-1-one
-
-
6-hydroxydihydro-beta-carboline
-
-
6His-tagged LPETG peptide
-
the synthetic sortase A substrate mimic is surface-recruited and inhibits biofilm formation of Staphylococcus aureus at 0.01-0.25 mM. 71.1% biofilm inhibition is observed with 100 mM peptide while on silicon coated rubber latex catheter, 45.82% inhibition is observed. The compound is designed based on the sortase A mechanism of action. LPETG is the conserved recognition motif near the C-terminus of the cell surface proteins of Staphylococcus aureus
-
7'-fluoro-6-hydroxy-2-(2-oxocyclohexylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
-
-
7-chloro-2-[4-[(Z)-2-(4-chlorophenyl)-1-cyanoethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
7-hydroxy-2,3,4,9-tetrahydro-1H-beta-carboline-1-carboxylic acid
-
-
7-methoxy-1-pentyl-2,3,4,9-tetrahydro-1H-beta-carboline
-
-
7-methoxy-1-phenyl-2,3,4,9-tetrahydro-1H-beta-carboline
-
-
7-methoxy-1-phenyl-4,9-dihydro-3H-beta-carboline
-
-
7-methoxy-2,3,4,9-tetrahydro-1H-beta-carboline-1-carboxylic acid
-
-
Ala-Leu-Pro-Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu
-
Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH''C(O)]-Glu-Glu
-
-
-
Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu
-
bacitracin
selectively binds and sequesters the C55-diphosphate species formed and recycled during lipid II synthesis. Analysis of the effect of the lipid II inhibiting antibiotic bacitracin on the incorporation of native and synthetic SrtA substrates, overview. The increased incorporation of specific SrtA synthetic substrates upon inhibition of lipid II suggests that lipid II does not seem to play a role in the incorporation of these substrates
benzyl [(2S)-1-(2-[[(2S)-1-[[(3R)-4-hydroxy-1-imino-2-oxopentan-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl]carbamate
benzyloxycarbonyl-Leu-Pro-Ala-Thr-CH2Cl
-
irreversible inhibitor of recombinant enzyme
benzyloxycarbonyl-Leu-Pro-Ala-Thr-CHN2
-
irreversible inhibitor of recombinant enzyme
beta-lactams
mimic the D-Ala-D-Ala motif and thereby inhibit the PBP-catalyzed transpeptidation reaction
-
beta-sitosterol-3-O-glucopyranoside
bis(4-ethoxy-2-phenyl-5-pyridazyl)disulfide
-
-
cis-1,2-bis(phenylsulfonyl)ethylene
-
IC50: 0.00113 mM, irreversible
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-leucyl)
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-valyl)
divinyl sulfone
-
IC50: 0.00106 mM, irreversible
ethyl 4-[3-(4-bromophenyl)-3-oxopropyl]piperazine-1-carboxylate
-
-
ethyl 6-amino-7'-fluoro-2-(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)spiro [[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carboxylate
-
-
ethyl 6-amino-7'-fluoro-2-(2-oxocycloheptylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carboxylate
-
-
ethyl 6-amino-7'-fluoro-2-(3-methyl-5-oxo-1-phenyl-1H-pyrazol-4(5H)-ylidene)-spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carboxylate
-
-
ethyl 6-amino-7'-fluoro-2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)spiro[[1,3] dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carboxylate
-
-
ethyl 6-amino-7'-fluoro-2-(5-methyl-2-oxocyclohexylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carboxylate
-
-
ethyl vinyl sulfone
-
IC50: 0.00471 mM, irreversible
galangin
-
IC50 for recombinant SrtA(DELTA24): 0.123 mM, no antibacterial activity against Staphylococcus aureus
galangin-3-methyl ether
-
IC50 for recombinant SrtA(DELTA24): 0.1179 mM, no antibacterial activity against Staphylococcus aureus
glycyl-L-threonyl-L-alpha-glutamyl-L-prolyl-L-leucinamide
-
37.7% inhibition at 0.2 mM
iodoacetamide
-
active site Cys184 of sortase A can be alkylated by iodoacetamide resulting in irreversible modified enzyme. The selenol and thiol of mutant Sec-sortase and mutant Hcy-sortase are sensitive to alkylation as well
isoaaptamine
-
the suppression of fibronectin-binding activity by isoaaptamine highlights its potential for the treatment of Staphylococcus aureus infections via inhibition of SrtA activity
isorhamnetin
-
IC50 for recombinant SrtA(DELTA24): 0.05886 mM, no antibacterial activity against Staphylococcus aureus
isorhamnetin 3-O-beta-D-rutinoside
-
-
kaempferol
-
IC50 for recombinant SrtA(DELTA24): 0.07794 mM, no antibacterial activity against Staphylococcus aureus
kaempferol-3-rutinoside
-
-
L-alanyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
23.9% inhibition at 0.2 mM
L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-leucyl-D-prolyl-L-alpha-glutamyl-L-threonylglycinamide
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonyl-L-phenylalaninamide
-
26.2% inhibition at 0.2 mM
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonyl-N2-methylglycinamide
-
19.4% inhibition at 0.2 mM
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
L-leucyl-L-prolyl-L-arginyl-L-alpha-asparagine
-
32.3% inhibition at 0.2 mM
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-phenylalaninamide
-
42.2% inhibition at 0.2 mM
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
L-leucyl-L-prolyl-N-[(2S)-5-[(2-amino-2-oxoethyl)(methyl)amino]-1-carboxy-3,5-dioxopentan-2-yl]-N5-(diaminomethylidene)-L-ornithinamide
-
68.5% inhibition at 0.2 mM, shows no activity in the growth inhibition assays
L-leucyl-L-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-cysteinyl-L-alaninamide
-
14.8% inhibition at 0.2 mM
L-leucyl-L-prolyl-N5-(diaminomethylidene)-L-ornithyl-N-[(2S)-1-carboxy-1-oxopropan-2-yl]-L-alpha-asparagine
-
29.2% inhibition at 0.2 mM
L-leucyl-L-prolyl-N5-(diaminomethylidene)-L-ornithyl-N-[(2S)-4-([2-[2-(2-amino-2-oxoethoxy)ethoxy]ethyl]amino)-3,4-dioxobutan-2-yl]-L-alpha-asparagine
-
30.4% inhibition at 0.2 mM
L-lysyl-L-seryl-L-phenylalanyl-L-leucyl-L-prolyl-L-alanyl-L-threonylglycylglycyl-L-alanyl-L-alpha-glutamine
-
18.1% inhibition at 0.2 mM
-
L-phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
70.1% inhibition at 0.2 mM
L-phenylalanyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
28.3% inhibition at 0.2 mM
Leu-Pro-Arg-Asp-Ala pentapeptide
-
LPRDA, the polypeptide possess antivirulence activity against Staphylococcus aureus, binding mechanism to sortase A, modelling, docking and molecular dynamics, overview. The previously reported partially chaotic movement of the beta6/beta7 and beta7/beta8 loops of SrtA (being the intrinsically disordered parts related to the SrtA binding site) is enhanced when SrtA is complexed with LPRDA, which in turn reveals all the signs of the flexible and structurally disordered molecule. Analysis of enzyme crystal structures: PDB IDs 2KID, 6R1V, 1IJA, 2MLM, 1T2P, 1T2O, and 1T2W. The presence of Ca2+ in its binding site within SrtA causes the restriction in the mobility of the loops and hence the intrinsic disorder
-
LPXTG
-
peptide formed from the ligation recognition sequence of enzyme SrtA. In the LPXTG-SrtA complex, the ligand is located within a hydrophobic cavity. Analysis of the binding pose of the LPXTG sequence with SrtA using the crystal structure of the complex (PDB ID 2KID)
-
maltol 3-O-(4'-O-p-coumaroyl-6'-O-(3-hydroxy-3-methylglutaroyl))-beta-glucopyranoside
-
-
maltol-3-O-(4'-O-cis-p-coumaroyl-6'-O-(3-hydroxy-3-methylglutaroyl))-beta-glucopyranoside
-
-
methyl (2E)-2,3-bis(4-methoxyphenyl)acrylate
-
IC50: 0.231 mM
methyl (2E)-3-(4-methoxycyclohexa-2,4-dien-1-yl)-2-(4-methoxyphenyl)prop-2-enoate
-
-
methyl (2S,3S,7aS)-2-ethenesulfonyl-5-oxo-3-phenyltetrahydropyrrolizine-7a-carboxylate
-
-
methyl (2S,3S,7aS)-2-ethenesulfonyl-5-oxo-3-pyridin-3-yl-tetrahydropyrrolizine-7a-carboxylate
-
-
methyl (2S,3S,7aS)-3-(3,4-dimethoxyphenyl)-2-ethenesulfonyl-5-oxotetrahydropyrrolizine-7a-carboxylate
-
-
methyl (2S,4S,5S)-4-ethenesulfonyl-2-(2-methoxycarbonylethyl)-5-pyridin-3-yl-pyrrolidine-2-carboxylate
-
-
methyl (2Z)-2,3-bis(4-methoxyphenyl)acrylate
-
IC50: 0.909 mM
methyl (4S,5S)-4-(ethenylsulfonyl)-5-(2-fluorophenyl)-L-prolinate
-
-
methyl (4S,5S)-4-(ethenylsulfonyl)-5-(3-fluorophenyl)-L-prolinate
-
-
methyl (4S,5S)-4-(ethenylsulfonyl)-5-phenyl-L-prolinate
-
-
methyl 1-aminoadamantan-3-carboxylate
-
-
methyl 2-morpholin-4-yl-5-[[(2E)-3-(2-thienyl)prop-2-enoyl]amino]benzoate
-
-
methyl 3-(3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamido)adamantane-1-carboxylate
-
-
methyl 3-(3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamido)adamantane-1-carboxylate
-
-
methyl 4-[3-(dimethylamino)propanoyl]benzenesulfinate
-
-
methyl 5-hydroxy-1H-indole-3-carboxylate
-
-
methyl 5-[[(2E)-3-(2-furyl)prop-2-enoyl]amino]-2-morpholin-4-ylbenzoate
-
-
methyl 5-[[(2E)-3-(furan-2-yl)prop-2-enoyl]amino]-2-(morpholin-4-yl)benzoate
-
-
methyl vinyl sulfone
-
IC50: 0.00624 mM, irreversible
morin
-
IC50 for recombinant SrtA(DELTA24): 0.03739 mM, no antibacterial activity against Staphylococcus aureus
N'-(2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetyl)adamantane-1-carbohydrazide
-
-
N'-(3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanoyl)adamantane-1-carbohydrazide
-
-
N'-(3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanoyl)adamantane-1-carbohydrazide
-
-
N-(1H-benzimidazol-5-yl)acridin-9-amine
N-(3,5-dimethyladamantan-1-yl)-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetamide
-
-
N-(3,5-dimethyladamantan-1-yl)-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
-
-
N-(3,5-dimethyladamantan-1-yl)-3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
-
-
N-(3-hydroxy-5,7-dimethyladamantan-1-yl)-2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetamide
-
-
N-(3-hydroxy-5,7-dimethyladamantan-1-yl)-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
-
-
N-(3-hydroxy-5,7-dimethyladamantan-1-yl)-3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
-
-
N-(3-hydroxyadamantan-1-yl)-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
-
-
N-(3-ydroxyadamantan-1-yl)-3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
-
-
N-(5-((3-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)acetamide
-
-
N-(5-((3-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)furan-2-carboxamide
-
-
N-(5-((3-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)isonicotinamide
-
-
N-(5-((3-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)nicotinamide
-
-
N-(5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)acetamide
-
-
N-(5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)isonicotinamide
-
-
N-(5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)nicotinamide
-
-
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
N-(adamantan-1-yl)-3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
-
-
N-(naphthalen-2-yl)-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
47.4% inhibition at 0.2 mM
N-acetyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
20.7% inhibition at 0.2 mM
N-adamantan-1-yl-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-alpha-glutamyl-L-prolyl-L-threoninamide
-
15.1% inhibition at 0.2 mM
N-benzoyl-L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonyl-L-prolinamide
-
108.4% inhibition at 0.2 mM
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
37.2% inhibition at 0.2 mM
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-phenylalaninamide
-
113.4% inhibition at 0.2 mM
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-prolinamide
-
31.0% inhibition at 0.2 mM
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide
N-[(3R,6R,9R,12S,13S,17S,22aR)-6-benzyl-3-[(4-hydroxyphenyl)methyl]-5,9,12-trimethyl-1,4,7,10,15,18-hexaoxo-17-(propan-2-yl)icosahydro-12H-pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacycloicosin-13-yl]acetamide
N-[(benzyloxy)carbonyl]-4-oxo-L-norvalylprolyl-N1-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-glutamamide
N-[(benzyloxy)carbonyl]-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
17.0% inhibition at 0.2 mM
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-alaninamide
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-2-hydroxy-6-[hydroxy(oxo)phenyl-lambda6-sulfanyl]-4-oxohex-5-en-3-yl]-L-alaninamide
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-6-cyano-2-hydroxy-4-oxohex-5-en-3-yl]-L-alaninamide
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(ethyldisulfanyl)benzamide
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(methyldisulfanyl)benzamide
N-[[2-(2-aminoethoxy)ethoxy]acetyl]-L-leucyl-L-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
-
22.6% inhibition at 0.2 mM
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine
N2-[(2S)-2-[4-[(1S)-1-amino-3-methylbutyl]-1H-1,2,3-triazol-1-yl]propanoyl]-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
33.0% inhibition at 0.2 mM
NH2-YALPE-AlaPsi(PO2H-CH2)Gly-EE-NH2
-
nonhydrolyzable phosphinic peptidomimetic inhibitor of SrtA derived from the LPXTG substrate sequence, simple reversible competitive inhibitor
nisin
lantibiotic, recognizes the pyrophosphate moiety of lipid II by its N-terminus, which contains A and B lantionine rings. Its C-terminus (containing C, D, and E rings) is responsible for subsequent pore formation
p-hydroxymercuribenzoate
-
-
p-hydroxymercuribenzoic acid
-
-
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
penicillin G
mimic the D-Ala-D-Ala motif and thereby inhibit the PBP-catalyzed transpeptidation reaction
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
psammaplin A1
-
potential of this inhibitor for the treatment of Staphylococcus aureus infections
quercetin-3,3'-dimethyl ether
-
IC50 for recombinant SrtA(DELTA24): 0.05361 mM, no antibacterial activity against Staphylococcus aureus
telmisartan
-
strong inhibition
Tyr-Ala-Leu-Pro-Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2
-
Tyr-Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH''C(O)]-Glu-Glu-NH2
-
-
-
Tyr-Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2
-
Vancomycin
blocks transglycosylation and transpeptidation reactions by its specific binding to the sterically accessible D-Ala-D-Ala terminus and its bulky structure. Binding of vancomycin to D-Ala-D-Ala within the sortase substrate increased transpeptidation by SrtA
[2-(trimethylammonium)ethyl]methanethiosulfonate
-
the inhibitor interferes with the cleavage of sorting signals at the LPXTG motif
[3-(5-bromo-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](1-methyl-1H-indol-3-yl)methanone
-
-
[3-(5-bromo-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-1H-indol-3-yl)methanone
-
-
[3-(5-bromo-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-1H-indol-3-yl)methanone
-
-
[3-(5-bromo-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
[3-(5-chloro-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](1-methyl-1H-indol-3-yl)methanone
-
-
[3-(5-chloro-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](1-methyl-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
[3-(5-methoxy-1-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](1-methyl-1H-indol-3-yl)methanone
-
-
[3-(5-methoxy-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
[4-(6-bromo-1H-indol-3-yl)-1H-imidazol-2-yl](1H-indol-3-yl)methanone
[4-(6-bromo-1H-indol-3-yl)-1H-imidazol-2-yl](6-hydroxy-1H-indol-3-yl)methanone
(2-amino-6-chloro-1H-indol-3-yl)(morpholin-4-yl)methanone

-
-
(2-amino-6-chloro-1H-indol-3-yl)(morpholin-4-yl)methanone
-
-
(2-amino-6-chloro-1H-indol-3-yl)(morpholin-4-yl)methanone
-
-
(2-amino-6-chloro-1H-indol-3-yl)(morpholin-4-yl)methanone
-
-
(2-amino-6-chloro-1H-indol-3-yl)(morpholin-4-yl)methanone
-
-
(2-amino-6-chloro-1H-indol-3-yl)(morpholin-4-yl)methanone
-
-
(2-amino-6-chloro-1H-indol-3-yl)(morpholin-4-yl)methanone
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,3-dihydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
(2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one

-
-
(2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one
-
-
(2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one
-
-
(2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one
-
-
(2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one
-
-
(2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
(2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one

-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
(2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2S)-2-[[(2R)-2-[[(2R)-2-([(2R)-1-[(2S)-2-[[(3S,4S)-3-acetamido-4-hydroxypentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino)-3-(4-hydroxyphenyl)propanoyl](methyl)amino]-3-phenylpropanoyl]amino]propanoic acid

-
-
(2S)-2-[[(2R)-2-[[(2R)-2-([(2R)-1-[(2S)-2-[[(3S,4S)-3-acetamido-4-hydroxypentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino)-3-(4-hydroxyphenyl)propanoyl](methyl)amino]-3-phenylpropanoyl]amino]propanoic acid
-
-
(2S)-2-[[(2R)-2-[[(2R)-2-([(2R)-1-[(2S)-2-[[(3S,4S)-3-acetamido-4-hydroxypentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino)-3-(4-hydroxyphenyl)propanoyl](methyl)amino]-3-phenylpropanoyl]amino]propanoic acid
-
-
(2S)-2-[[(2R)-2-[[(2R)-2-([(2R)-1-[(2S)-2-[[(3S,4S)-3-acetamido-4-hydroxypentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino)-3-(4-hydroxyphenyl)propanoyl](methyl)amino]-3-phenylpropanoyl]amino]propanoic acid
-
-
(2S)-2-[[(2R)-2-[[(2R)-2-([(2R)-1-[(2S)-2-[[(3S,4S)-3-acetamido-4-hydroxypentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino)-3-(4-hydroxyphenyl)propanoyl](methyl)amino]-3-phenylpropanoyl]amino]propanoic acid
-
-
(2S)-2-[[(2R)-2-[[(2R)-2-([(2R)-1-[(2S)-2-[[(3S,4S)-3-acetamido-4-hydroxypentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino)-3-(4-hydroxyphenyl)propanoyl](methyl)amino]-3-phenylpropanoyl]amino]propanoic acid
-
-
(2S)-2-[[(2R)-2-[[(2R)-2-([(2R)-1-[(2S)-2-[[(3S,4S)-3-acetamido-4-hydroxypentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino)-3-(4-hydroxyphenyl)propanoyl](methyl)amino]-3-phenylpropanoyl]amino]propanoic acid
-
-
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione

-
-
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione
-
-
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione
-
-
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione
-
-
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione
-
-
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione
-
-
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione
-
-
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone

-
-
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone
-
-
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone
-
-
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone
-
-
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone
-
-
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone
-
-
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone
-
-
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone

-
-
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone
-
-
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone
-
-
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone
-
-
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone
-
-
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone
-
-
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone
-
-
2-(2-amino-3-chlorobenzamido)benzoic acid

-
-
2-(2-amino-3-chlorobenzamido)benzoic acid
-
-
2-(2-amino-3-chlorobenzamido)benzoic acid
-
-
2-(2-amino-3-chlorobenzamido)benzoic acid
-
-
2-(2-amino-3-chlorobenzamido)benzoic acid
-
-
2-(2-amino-3-chlorobenzamido)benzoic acid
-
-
2-(2-amino-3-chlorobenzamido)benzoic acid
-
-
2-[(2-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one

-
-
2-[(2-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(2-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(2-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(2-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(2-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(2-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(3-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one

-
-
2-[(3-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(3-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(3-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(3-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(3-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(3-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(4-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one

-
-
2-[(4-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(4-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(4-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(4-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(4-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[(4-fluorophenyl)[(pyridin-2-yl)amino]methyl]-3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one
-
-
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide

-
-
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
-
-
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
-
-
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
-
-
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
-
-
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
-
-
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-dihydroxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide

-
-
2-[4-[(Z)-1-cyano-2-(3,4-dihydroxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-dihydroxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-dihydroxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-dihydroxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-dihydroxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-dihydroxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-diphenoxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide

-
-
2-[4-[(Z)-1-cyano-2-(3,4-diphenoxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-diphenoxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-diphenoxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-diphenoxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-diphenoxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-(3,4-diphenoxyphenyl)ethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-phenylethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide

-
-
2-[4-[(Z)-1-cyano-2-phenylethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-phenylethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-phenylethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-phenylethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-phenylethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
2-[4-[(Z)-1-cyano-2-phenylethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
3',3''-dihydroxy-(-)-matairesinol

-
-
3',3''-dihydroxy-(-)-matairesinol
-
-
3',3''-dihydroxy-(-)-matairesinol
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-1-chloro-1,3,5-trideoxy-D-glycero-pent-2-ulose

-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-1-chloro-1,3,5-trideoxy-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-1-chloro-1,3,5-trideoxy-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-1-chloro-1,3,5-trideoxy-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-1-chloro-1,3,5-trideoxy-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-1-chloro-1,3,5-trideoxy-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-1-chloro-1,3,5-trideoxy-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-3,5-dideoxy-1-thio-D-glycero-pent-2-ulose

-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-3,5-dideoxy-1-thio-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-3,5-dideoxy-1-thio-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-3,5-dideoxy-1-thio-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-3,5-dideoxy-1-thio-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-3,5-dideoxy-1-thio-D-glycero-pent-2-ulose
-
-
3-([N-[(benzyloxy)carbonyl]-L-leucylprolyl-L-alanyl]amino)-3,5-dideoxy-1-thio-D-glycero-pent-2-ulose
-
-
3-hydroxy-6-(hydroxymethyl)-2-[(4-methoxyphenyl)[(pyridin-2-yl)amino]methyl]-4H-pyran-4-one

-
-
3-hydroxy-6-(hydroxymethyl)-2-[(4-methoxyphenyl)[(pyridin-2-yl)amino]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[(4-methoxyphenyl)[(pyridin-2-yl)amino]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[(4-methoxyphenyl)[(pyridin-2-yl)amino]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[(4-methoxyphenyl)[(pyridin-2-yl)amino]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[(4-methoxyphenyl)[(pyridin-2-yl)amino]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[(4-methoxyphenyl)[(pyridin-2-yl)amino]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino](thiophen-3-yl)methyl]-4H-pyran-4-one

-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino](thiophen-3-yl)methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino](thiophen-3-yl)methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino](thiophen-3-yl)methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino](thiophen-3-yl)methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino](thiophen-3-yl)methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino](thiophen-3-yl)methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino][4-(trifluoromethyl)phenyl]methyl]-4H-pyran-4-one

-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino][4-(trifluoromethyl)phenyl]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino][4-(trifluoromethyl)phenyl]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino][4-(trifluoromethyl)phenyl]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino][4-(trifluoromethyl)phenyl]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino][4-(trifluoromethyl)phenyl]methyl]-4H-pyran-4-one
-
-
3-hydroxy-6-(hydroxymethyl)-2-[[(pyridin-2-yl)amino][4-(trifluoromethyl)phenyl]methyl]-4H-pyran-4-one
-
-
3-[(1H-indol-3-yl)methyl]-2H-1-benzopyran-2,4(3H)-dione

-
-
3-[(1H-indol-3-yl)methyl]-2H-1-benzopyran-2,4(3H)-dione
-
-
3-[(1H-indol-3-yl)methyl]-2H-1-benzopyran-2,4(3H)-dione
-
-
3-[(1H-indol-3-yl)methyl]-2H-1-benzopyran-2,4(3H)-dione
-
-
3-[(1H-indol-3-yl)methyl]-2H-1-benzopyran-2,4(3H)-dione
-
-
3-[(1H-indol-3-yl)methyl]-2H-1-benzopyran-2,4(3H)-dione
-
-
3-[(1H-indol-3-yl)methyl]-2H-1-benzopyran-2,4(3H)-dione
-
-
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione

-
-
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
-
-
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
-
-
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
-
-
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
-
-
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
-
-
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
-
-
5-(2-fluoro-5-methoxyphenyl)-4-(hydroxymethyl)-1-methylproline

-
-
5-(2-fluoro-5-methoxyphenyl)-4-(hydroxymethyl)-1-methylproline
-
-
5-(2-fluoro-5-methoxyphenyl)-4-(hydroxymethyl)-1-methylproline
-
-
5-(2-fluoro-5-methoxyphenyl)-4-(hydroxymethyl)-1-methylproline
-
-
5-(2-fluoro-5-methoxyphenyl)-4-(hydroxymethyl)-1-methylproline
-
-
5-(2-fluoro-5-methoxyphenyl)-4-(hydroxymethyl)-1-methylproline
-
-
5-(2-fluoro-5-methoxyphenyl)-4-(hydroxymethyl)-1-methylproline
-
-
5-chloro-2-(methanesulfonyl)-N-(3-phenoxyphenyl)pyrimidine-4-carboxamide

-
-
5-chloro-2-(methanesulfonyl)-N-(3-phenoxyphenyl)pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-(3-phenoxyphenyl)pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-(3-phenoxyphenyl)pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-(3-phenoxyphenyl)pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-(3-phenoxyphenyl)pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-(3-phenoxyphenyl)pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-[2-oxo-3-(3-phenoxyphenyl)propyl]pyrimidine-4-carboxamide

-
-
5-chloro-2-(methanesulfonyl)-N-[2-oxo-3-(3-phenoxyphenyl)propyl]pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-[2-oxo-3-(3-phenoxyphenyl)propyl]pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-[2-oxo-3-(3-phenoxyphenyl)propyl]pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-[2-oxo-3-(3-phenoxyphenyl)propyl]pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-[2-oxo-3-(3-phenoxyphenyl)propyl]pyrimidine-4-carboxamide
-
-
5-chloro-2-(methanesulfonyl)-N-[2-oxo-3-(3-phenoxyphenyl)propyl]pyrimidine-4-carboxamide
-
-
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione

-
-
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione
-
-
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione
-
-
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione
-
-
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione
-
-
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione
-
-
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione
-
-
7-chloro-2-[4-[(Z)-2-(4-chlorophenyl)-1-cyanoethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide

-
-
7-chloro-2-[4-[(Z)-2-(4-chlorophenyl)-1-cyanoethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
7-chloro-2-[4-[(Z)-2-(4-chlorophenyl)-1-cyanoethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
7-chloro-2-[4-[(Z)-2-(4-chlorophenyl)-1-cyanoethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
7-chloro-2-[4-[(Z)-2-(4-chlorophenyl)-1-cyanoethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
7-chloro-2-[4-[(Z)-2-(4-chlorophenyl)-1-cyanoethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
7-chloro-2-[4-[(Z)-2-(4-chlorophenyl)-1-cyanoethenyl]phenyl]-N-(2-methylpropyl)-2,3-dihydro-1-benzofuran-3-carboxamide
-
-
Ala-Leu-Pro-Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu

-
-
-
Ala-Leu-Pro-Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu
-
-
-
Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu

-
-
-
Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu
-
-
-
Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu
-
-
-
Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu
-
-
-
Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu
-
-
-
benzyl [(2S)-1-(2-[[(2S)-1-[[(3R)-4-hydroxy-1-imino-2-oxopentan-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl]carbamate

-
-
benzyl [(2S)-1-(2-[[(2S)-1-[[(3R)-4-hydroxy-1-imino-2-oxopentan-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl]carbamate
-
-
benzyl [(2S)-1-(2-[[(2S)-1-[[(3R)-4-hydroxy-1-imino-2-oxopentan-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl]carbamate
-
-
benzyl [(2S)-1-(2-[[(2S)-1-[[(3R)-4-hydroxy-1-imino-2-oxopentan-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl]carbamate
-
-
benzyl [(2S)-1-(2-[[(2S)-1-[[(3R)-4-hydroxy-1-imino-2-oxopentan-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl]carbamate
-
-
benzyl [(2S)-1-(2-[[(2S)-1-[[(3R)-4-hydroxy-1-imino-2-oxopentan-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl]carbamate
-
-
benzyl [(2S)-1-(2-[[(2S)-1-[[(3R)-4-hydroxy-1-imino-2-oxopentan-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl]carbamate
-
-
berberine chloride

-
potential of this inhibitor for the treatment of Staphylococcus aureus infections
beta-sitosterol-3-O-glucopyranoside

-
potential of this inhibitor for the treatment of Staphylococcus aureus infections
beta-sitosterol-3-O-glucopyranoside
-
-
beta-sitosterol-3-O-glucopyranoside
-
IC50: 18.3 mg/L
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-leucyl)

-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-leucyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-leucyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-leucyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-leucyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-leucyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-leucyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-valyl)

-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-valyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-valyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-valyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-valyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-valyl)
-
-
cyclo(L-alanyl-N-methyl-L-phenylalanyl-L-tyrosyl-L-prolyl-L-valyl)
-
-
L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-leucyl-D-prolyl-L-alpha-glutamyl-L-threonylglycinamide

-
-
L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-leucyl-D-prolyl-L-alpha-glutamyl-L-threonylglycinamide
-
-
L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-leucyl-D-prolyl-L-alpha-glutamyl-L-threonylglycinamide
-
-
L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-leucyl-D-prolyl-L-alpha-glutamyl-L-threonylglycinamide
-
-
L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-leucyl-D-prolyl-L-alpha-glutamyl-L-threonylglycinamide
-
-
L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-leucyl-D-prolyl-L-alpha-glutamyl-L-threonylglycinamide
-
-
L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-leucyl-D-prolyl-L-alpha-glutamyl-L-threonylglycinamide
-
-
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide

-
-
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide

-
-
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
-
-
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
-
76.0% inhibition at 0.2 mM
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
-
-
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
-
-
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
-
-
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
-
-
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
-
-
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide

-
-
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
ML346

-
-
-
myricetin

-
IC50 for recombinant SrtA(DELTA24): 0.04403 mM, no antibacterial activity against Staphylococcus aureus
N-(1H-benzimidazol-5-yl)acridin-9-amine

-
-
N-(1H-benzimidazol-5-yl)acridin-9-amine
-
-
N-(1H-benzimidazol-5-yl)acridin-9-amine
-
-
N-(1H-benzimidazol-5-yl)acridin-9-amine
-
-
N-(1H-benzimidazol-5-yl)acridin-9-amine
-
-
N-(1H-benzimidazol-5-yl)acridin-9-amine
-
-
N-(1H-benzimidazol-5-yl)acridin-9-amine
-
-
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide

-
-
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide
-
-
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide
-
-
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide
-
-
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide
-
-
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide
-
-
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide
-
-
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide

-
-
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
-
-
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
-
-
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
-
-
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
-
-
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
-
-
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide

-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
23.3% inhibition at 0.2 mM
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide

-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
-
-
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide

-
-
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide
-
-
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide
-
-
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide
-
-
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide
-
-
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide
-
-
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide
-
-
N-[(3R,6R,9R,12S,13S,17S,22aR)-6-benzyl-3-[(4-hydroxyphenyl)methyl]-5,9,12-trimethyl-1,4,7,10,15,18-hexaoxo-17-(propan-2-yl)icosahydro-12H-pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacycloicosin-13-yl]acetamide

-
-
N-[(3R,6R,9R,12S,13S,17S,22aR)-6-benzyl-3-[(4-hydroxyphenyl)methyl]-5,9,12-trimethyl-1,4,7,10,15,18-hexaoxo-17-(propan-2-yl)icosahydro-12H-pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacycloicosin-13-yl]acetamide
-
-
N-[(3R,6R,9R,12S,13S,17S,22aR)-6-benzyl-3-[(4-hydroxyphenyl)methyl]-5,9,12-trimethyl-1,4,7,10,15,18-hexaoxo-17-(propan-2-yl)icosahydro-12H-pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacycloicosin-13-yl]acetamide
-
-
N-[(3R,6R,9R,12S,13S,17S,22aR)-6-benzyl-3-[(4-hydroxyphenyl)methyl]-5,9,12-trimethyl-1,4,7,10,15,18-hexaoxo-17-(propan-2-yl)icosahydro-12H-pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacycloicosin-13-yl]acetamide
-
-
N-[(3R,6R,9R,12S,13S,17S,22aR)-6-benzyl-3-[(4-hydroxyphenyl)methyl]-5,9,12-trimethyl-1,4,7,10,15,18-hexaoxo-17-(propan-2-yl)icosahydro-12H-pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacycloicosin-13-yl]acetamide
-
-
N-[(3R,6R,9R,12S,13S,17S,22aR)-6-benzyl-3-[(4-hydroxyphenyl)methyl]-5,9,12-trimethyl-1,4,7,10,15,18-hexaoxo-17-(propan-2-yl)icosahydro-12H-pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacycloicosin-13-yl]acetamide
-
-
N-[(3R,6R,9R,12S,13S,17S,22aR)-6-benzyl-3-[(4-hydroxyphenyl)methyl]-5,9,12-trimethyl-1,4,7,10,15,18-hexaoxo-17-(propan-2-yl)icosahydro-12H-pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacycloicosin-13-yl]acetamide
-
-
N-[(benzyloxy)carbonyl]-4-oxo-L-norvalylprolyl-N1-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-glutamamide

-
-
N-[(benzyloxy)carbonyl]-4-oxo-L-norvalylprolyl-N1-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-glutamamide
-
-
N-[(benzyloxy)carbonyl]-4-oxo-L-norvalylprolyl-N1-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-glutamamide
-
-
N-[(benzyloxy)carbonyl]-4-oxo-L-norvalylprolyl-N1-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-glutamamide
-
-
N-[(benzyloxy)carbonyl]-4-oxo-L-norvalylprolyl-N1-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-glutamamide
-
-
N-[(benzyloxy)carbonyl]-4-oxo-L-norvalylprolyl-N1-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-glutamamide
-
-
N-[(benzyloxy)carbonyl]-4-oxo-L-norvalylprolyl-N1-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-glutamamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-alaninamide

-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(2R,3R)-3-hydroxy-1-sulfanylbutan-2-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-2-hydroxy-6-[hydroxy(oxo)phenyl-lambda6-sulfanyl]-4-oxohex-5-en-3-yl]-L-alaninamide

-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-2-hydroxy-6-[hydroxy(oxo)phenyl-lambda6-sulfanyl]-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-2-hydroxy-6-[hydroxy(oxo)phenyl-lambda6-sulfanyl]-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-2-hydroxy-6-[hydroxy(oxo)phenyl-lambda6-sulfanyl]-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-2-hydroxy-6-[hydroxy(oxo)phenyl-lambda6-sulfanyl]-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-2-hydroxy-6-[hydroxy(oxo)phenyl-lambda6-sulfanyl]-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-2-hydroxy-6-[hydroxy(oxo)phenyl-lambda6-sulfanyl]-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-6-cyano-2-hydroxy-4-oxohex-5-en-3-yl]-L-alaninamide

-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-6-cyano-2-hydroxy-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-6-cyano-2-hydroxy-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-6-cyano-2-hydroxy-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-6-cyano-2-hydroxy-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-6-cyano-2-hydroxy-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-leucylprolyl-N-[(3R,5E)-6-cyano-2-hydroxy-4-oxohex-5-en-3-yl]-L-alaninamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(ethyldisulfanyl)benzamide

-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(ethyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(ethyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(ethyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(ethyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(ethyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(ethyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(methyldisulfanyl)benzamide

-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(methyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(methyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(methyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(methyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(methyldisulfanyl)benzamide
-
-
N-[2-[(adamantan-1-yl)amino]-2-oxoethyl]-2-(methyldisulfanyl)benzamide
-
-
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine

-
-
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine
-
-
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine
-
-
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine
-
-
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine
-
-
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine
-
-
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine
-
-
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide

-
-
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
-
-
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
-
-
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
-
-
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
-
-
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
-
-
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
-
-
phenyl vinyl sulfone

-
IC50 is 0.14332 mg/ml
phenyl vinyl sulfone
-
IC50: 0.736 mM, irreversible
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide

-
-
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
-
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
-
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
-
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
-
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
-
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
-
-
quercetin

-
IC50 for recombinant SrtA(DELTA24): 0.0527 mM, no antibacterial activity against Staphylococcus aureus
quercitrin

-
-
rutin

-
-
Tyr-Ala-Leu-Pro-Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2

-
-
-
Tyr-Ala-Leu-Pro-Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2
-
-
-
Tyr-Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2

-
-
-
Tyr-Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2
-
-
-
Tyr-Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2
-
-
-
Tyr-Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2
-
-
-
Tyr-Ala-Leu_Pro_Glu-PSI[NHCH2[CH3]P[(O)(OH)]CH2CH2C(O)]-Glu-Glu-NH2
-
-
-
[3-(5-bromo-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone

-
-
[3-(5-bromo-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-bromo-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-bromo-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-bromo-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-bromo-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-bromo-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone

-
-
[3-(5-fluoro-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-fluoro-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-fluoro-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-methoxy-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone

-
-
[3-(5-methoxy-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-methoxy-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-methoxy-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-methoxy-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-methoxy-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[3-(5-methoxy-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl](5-methoxy-1-methyl-2,3-dihydro-1H-indol-3-yl)methanone
-
-
[4-(6-bromo-1H-indol-3-yl)-1H-imidazol-2-yl](1H-indol-3-yl)methanone

-
IC50: 19.44 mg/L
[4-(6-bromo-1H-indol-3-yl)-1H-imidazol-2-yl](1H-indol-3-yl)methanone
-
-
[4-(6-bromo-1H-indol-3-yl)-1H-imidazol-2-yl](6-hydroxy-1H-indol-3-yl)methanone

-
IC50: 16.7 mg/L
[4-(6-bromo-1H-indol-3-yl)-1H-imidazol-2-yl](6-hydroxy-1H-indol-3-yl)methanone
-
-
additional information

-
aryl (beta-amino)ethyl ketones inhibit sortase enzymes. Inhibition of sortases occurs through an irreversible, covalent modification of their active site cysteine. Sortases specifically activate this class of molecules via beta-elimination, generating a reactive olefin intermediate that covalently modifies the cysteine thiol
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one and (2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one and (2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one
-
additional information
-
small molecule and peptidomimetic inhibitors of sortase A towards antivirulence treatment, overview. Binding structures of non-covalent peptidomimetic inhibitors of SrtA
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one, (2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one, and (2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
additional information
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one, (2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one, and (2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one, (2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one, and (2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
additional information
-
small molecule and peptidomimetic inhibitors of sortase A towards antivirulence treatment, overview. Binding structures of non-covalent peptidomimetic inhibitors of SrtA
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one, (2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-3-(2-hydroxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1,3-bis(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(2,4-dihydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one, and (2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one, (2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one and (2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview
-
additional information
-
SrtA activity is a prime target for inhibition of Staphylococcus aureus colonization
-
additional information
-
no inhibition by (3R,6S)-3,6-bis(6-bromo-1H-indol-3-yl)piperazin-2-one and (3R,6S)-3,6-bis(6-bromo-1H-indol-3-yl)piperazin-2-one
-
additional information
-
no inhibition by phenyl trans-styryl sulfone
-
additional information
-
no inhibition by trans-stilbene
-
additional information
-
aryl (beta-amino)ethyl ketones inhibit sortase enzymes. Inhibition of sortases occurs through an irreversible, covalent modification of their active site cysteine. Sortases specifically activate this class of molecules via beta-elimination, generating a reactive olefin intermediate that covalently modifies the cysteine thiol
-
additional information
-
anti-SrtA serum inhibits Staphylococcus aureus biofilm formation
-
additional information
-
not inhibited by 3-nitropropionate
-
additional information
-
small molecule library screening, synthesis and analysis of irreversible benzisothiazolinone-based inhibitors of the enzyme, structure-activity relationship, overview. No inhibition by aminoadamantan, methyl 1-aminoadamantan-3-carboxylate, and 2-(1-oxoisoindolin-2-yl)acetic acid. Structure determination of inhibitor 1-SrtA complex using purified recombinant nontagged truncated enzyme mutant variant SrtADELTA59, NMR structure determination and analysis
-
additional information
-
development of spiro[1,3]dithiine-4,11-indeno[1,2-b]quinoxaline derivatives as Staphylococcus aureus sortase A inhibitors. The selected derivatives show significant activity against the tested strains with microbicidal behavior. The active spiro-1,3-dithiinoindenoquinoxaline attenuate the in vitro virulence-related phenotype of SrtA by weakening the adherence of Staphylococcus aureus to fibrinogen and reducing the biofilm formation. antimicrobial screening of the synthesized compounds against five standard strains Staphylococcus aureus ATCC 33591, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa ATCC 27856, Escherichia coli ATCC 25922, and Candida albicans ATCC 90028, molecular docking simulations, overview. gamma-Radiation cannot degrade the chemical structure of the active derivatives as determined by the UV/VIS spectrophotometer, indicating the stability of the drugs after their sterilization by gamma radiation
-
additional information
-
5-(benzylthio)-1,3,4-thiadiazol-2-amine is inactive as inhibitor; high-throughput screening of small-molecule libraries and identification of thiadiazoles as a class of inhibitors against Staphylococcus aureus sortase A (SrtA). Inhibitor design and synthesis, mode of action through covalent binding to the active site cysteine, docking study, overview
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
additional information
-
L-phenylalanyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-phenylalaninamide is inactive as inhibitor; development of potent Sortase A inhibitors, synthesis of a series of peptidomimetic inhibitors of sortase A based on the sorting signal (LPXTG, where X represents any amino acid), supported by computational binding analysis. Growth inhibition assay using the compounds and Staphylococcus aureus. L-alpha-glutamyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide is inactive as inhibitor
-
additional information
-
small molecule and peptidomimetic inhibitors of sortase A towards antivirulence treatment, overview. Binding structures of non-covalent peptidomimetic inhibitors of SrtA
-
additional information
-
1,2,4-oxadiazole topsentin analogues as staphylococcal biofilm inhibitors targeting the bacterial transpeptidase sortase A, synthesis, overview. The ability of inhibiting biofilm formation is evaluated against both Gram-positive and Gram-negative pathogens
-
additional information
-
sortase A covalent inhibitors with benzofuranene cyanide structures as potential antibacterial agents against Staphylococcus aureus, Structure-activity relationships and docking studies, molecular dynamics simulations, overview. Synthesis of 2-(4-(1-cyano-2-phenylvinyl)phenyl)-N-isobutylbenzofuran-3-carboxamide derivatives. The acrylonitrile moiety of the compounds plays an important role in enhancing the activity. When the double bond of acrylonitrile is changed to single bond, the activity is decreased significantly. This indicates that acrylonitrile, which is a Michael receptor, can inhibit the activity of SrtA by covalent binding effectively to the thiol group of Cys184
-
additional information
-
inhibitor screening, molecular docking, molecular dynamics simulations, MM/PBSA method, overview. No inhibition by 2,3-bis(4-methoxyphenyl)propanenitrile
-
additional information
-
small molecule and peptidomimetic inhibitors of sortase A towards antivirulence treatment, overview. Binding structures of non-covalent peptidomimetic inhibitors of SrtA
-
additional information
-
sortase A inhibitory metabolites from the flowers of Sophora japonica, overview
-
additional information
minimal inhibition concentrations of the inhibitory compounds, docking analysis in the binding site of the Streptococcus mutans SrtA enzyme, detailed overview. Molecular dynamic simulations and molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculation analysis with compounds (2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, and (2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
additional information
-
small molecule and peptidomimetic inhibitors of sortase A towards antivirulence treatment, overview. Binding structures of non-covalent peptidomimetic inhibitors of SrtA
-
additional information
inhibition of Streptococcus mutans adhesion and biofilm formation with small-molecule inhibitors of sortase A from Juniperus chinensis. Effect of SrtA inhibitor on bacterial cell aggregation induced by human saliva, inhibition kinetics, overview
-
additional information
-
small molecule and peptidomimetic inhibitors of sortase A towards antivirulence treatment, overview. Binding structures of non-covalent peptidomimetic inhibitors of SrtA
-
additional information
-
small molecule and peptidomimetic inhibitors of sortase A towards antivirulence treatment, overview. Binding structures of non-covalent peptidomimetic inhibitors of SrtA. Substrate analogue (Abz-LPATAG, pdb 7S51[31a]) binds to Streptococcus pyogenes SrtA similar to Cbz-LPAT
-
additional information
-
minimal inhibition concentrations of the inhibitory compounds, overview. No inhibition by (2E)-1-(3-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(2-nitrophenyl)-3-(3-hydoxyphenyl)prop-2-en-1-one, (2E)-1-(2-hydroxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one,(2E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (2E)-3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one, (2E)-1-(3-bromophenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one, and (2E)-1-(3-bromophenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.275
(1E)-N'-[(1E)-(4-[(E)-[(diaminomethylene)hydrazono]methyl]phenyl)methylene]ethanehydrazonamide
Staphylococcus aureus
-
-
0.133
(2-methyl-1H-indol-3-yl)(oxo)acetic acid
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.476
(2E)-2,3-bis(4-methoxyphenyl)acrylamide
Staphylococcus aureus
-
IC50: 0.476 mM
0.187
(2E)-2,3-bis(4-methoxyphenyl)acrylonitrile
Staphylococcus aureus
-
IC50: 0.187 mM
0.15
(2E)-2-(2-furoyl)-3-[(methyl[4-[(5-nitropyridin-2-yl)oxy]phenyl]oxido-l4-sulfanylidene)amino]acrylonitrile
Staphylococcus aureus
-
-
0.111
(2E)-3-(2-furyl)-N-[3-(hydroxymethyl)-4-morpholin-4-ylphenyl]acrylamide
Staphylococcus aureus
-
-
0.4
(2E)-3-[(methyl[4-[(5-nitropyridin-2-yl)oxy]phenyl]oxido-l4-sulfanylidene)amino]-2-(2-thienylcarbonyl)acrylonitrile
Staphylococcus aureus
-
-
0.125
(2E)-4-([4-[(2-hydroxybenzoyl)amino]phenyl]amino)-4-oxobut-2-enoic acid
Staphylococcus aureus
-
-
0.107
(2E)-N-(3-formyl-4-morpholin-4-ylphenyl)-3-(2-furyl)acrylamide
Staphylococcus aureus
-
-
0.077
(2E)-N-(3-formyl-4-morpholin-4-ylphenyl)-3-(2-thienyl)acrylamide
Staphylococcus aureus
-
-
0.073
(2E)-N-[3-(hydroxymethyl)-4-morpholin-4-ylphenyl]-3-(2-thienyl)acrylamide
Staphylococcus aureus
-
-
0.0279
(2Z)-2,3-bis(4-methoxyphenyl)acrylonitrile
Staphylococcus aureus
-
IC50: 0.0279mM
0.009244
(2Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
Staphylococcus aureus
-
IC50: 0.009244 mM
0.0092
(2Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl)prop-2-enenitrile
Staphylococcus aureus
-
pH 7.5, 37°C
0.0362
(2Z)-3-(2-methoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
Staphylococcus aureus
-
IC50: 0.0362 mM
0.02296
(2Z)-3-(3,4-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
Staphylococcus aureus
-
IC50: 0.02296 mM
0.025463
(2Z)-3-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
Staphylococcus aureus
-
IC50: 0.025463 mM
0.0174
(2Z)-3-(3-methoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile
Staphylococcus aureus
-
IC50: 0.0174 mM
0.0062
(3aR,5S,9bR)-5-(2-phenylethyl)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2]benzopyran-2,6,9-trione
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.023
(4,5-dichloro-1H-pyrrol-2-yl)[2-hydroxy-3-(4-methylpentyl)phenyl]methanone
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0052
(4E)-5-methyl-4-[[(4-nitrophenyl)amino]methylidene]-2-phenyl-2,4-dihydro-3H-pyrazole-3-thione
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.119
(5Z)-3-(2,4-dimethylphenyl)-5-(3-nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
1
(5Z)-3-(3-chlorophenyl)-5-(4-methyl-3-nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
IC50 above 1.0 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.492
(5Z)-3-benzyl-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.104
(5Z)-3-ethyl-5-(2-nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0037
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-(2,4-dimethylphenyl)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.017
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-(3-chlorophenyl)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.015
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-(3-methylphenyl)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.012
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-(4-nitrophenyl)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.014
(5Z)-5-(3-bromo-2-hydroxy-5-nitrobenzylidene)-3-phenyl-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.035
(5Z)-5-(3-bromo-4-hydroxy-5-nitrobenzylidene)-3-(2,4-dimethylphenyl)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.109
(5Z)-5-(3-chlorobenzylidene)-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.199
(5Z)-5-benzylidene-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.405
(5Z)-5-benzylidene-3-methyl-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.186
(5Z)-5-benzylidene-3-propyl-2-thioxo-1,3-thiazolidin-4-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0322
(Z)-2-(4-(1-cyano-2-(2,4,6-methylphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0379
(Z)-2-(4-(1-cyano-2-(2,4,6-methylphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0141 - 0.0218
(Z)-2-(4-(1-cyano-2-(2,5-methoxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
0.0528
(Z)-2-(4-(1-cyano-2-(2,5-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0097
(Z)-2-(4-(1-cyano-2-(2-carboxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0284
(Z)-2-(4-(1-cyano-2-(2-carboxyphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0033 - 0.0096
(Z)-2-(4-(1-cyano-2-(3,4-benzyloxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
0.0145
(Z)-2-(4-(1-cyano-2-(3,4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0491
(Z)-2-(4-(1-cyano-2-(3,4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0175
(Z)-2-(4-(1-cyano-2-(3,4-methylphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.1
(Z)-2-(4-(1-cyano-2-(3,4-methylphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0122
(Z)-2-(4-(1-cyano-2-(4-(trifluoromethyl)phenyl)vinyl)phenyl)-N-isobutylbenzofuran-3-carboxamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.006
(Z)-2-(4-(1-cyano-2-(4-benzyloxyphenyl)vinyl)phenyl)-Nisobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
above, pH 7.5, 37°C
0.0191
(Z)-2-(4-(1-cyano-2-(4-bromophenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0155
(Z)-2-(4-(1-cyano-2-(4-bromophenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
above, pH 7.5, 37°C
0.0164 - 0.1
(Z)-2-(4-(1-cyano-2-(4-bromophenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
0.0098
(Z)-2-(4-(1-cyano-2-(4-chlorophenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0059 - 0.0101
(Z)-2-(4-(1-cyano-2-(4-chlorophenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
0.0068
(Z)-2-(4-(1-cyano-2-(4-chlorophenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0094
(Z)-2-(4-(1-cyano-2-(4-ethylphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0486
(Z)-2-(4-(1-cyano-2-(4-ethylphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0197
(Z)-2-(4-(1-cyano-2-(4-fluorophenyl)vinyl)phenyl)-N-isobutylbenzofuran-3-carboxamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0119
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0121
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0138 - 0.0641
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
0.0471
(Z)-2-(4-(1-cyano-2-(4-methylphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0119
(Z)-2-(4-(1-cyano-2-phenylvinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0299
(Z)-2-(4-(1-cyano2-phenylvinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.1514
1-(2,4-dihydroxy-6-methoxyphenyl)ethan-1-one
Streptococcus mutans
pH 7.2, 37°C, recombinant enzyme
0.0896 - 0.736
1-(3,4-dichlorophenyl)-3-(dimethylamino)propan-1-one
0.0569 - 0.0837
1-(4-bromophenyl)-3-(3-methylpiperidin-1-yl)propan-1-one
0.0844 - 0.0906
1-(4-chlorophenyl)-3-morpholin-4-ylpropan-1-one
0.0472 - 0.0891
1-(4-fluorophenyl)-3-morpholin-4-ylpropan-1-one
0.0569 - 0.0889
1-(4-methylphenyl)-3-morpholin-4-ylpropan-1-one
0.0106
1-phenyl-2,3,4,9-tetrahydro-1H-beta-carbolin-7-ol
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.097
1-phenyl-4,9-dihydro-3H-beta-carboline
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.4
1-[4-(2-aminopyrimidin-4-yl)phenyl]-3-(4-chlorophenyl)urea
Staphylococcus aureus
-
-
0.069
1H-indol-3-yl(oxo)acetic acid
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0079
2,2',4,5,5'-pentahydroxy-7,7'-dimethyl[1,1'-bianthracene]-9,9',10,10'-tetrone
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0517
2,5-dihydroxy-6-(propan-2-yl)cyclohepta-2,4,6-trien-1-one
Streptococcus mutans
pH 7.2, 37°C, recombinant enzyme
1.745
2-(((5-amino-1,3,4-thiadiazol-2-yl)thio)methyl)benzonitrile
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.071
2-((4-nitrobenzyl)thio)-5-(piperazin-1-yl)-1,3,4-thiadiazole
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.174
2-(1H-indol-3-yl)-2-oxo-N-phenylacetamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0397
2-(2-amino-3-chlorobenzamido)benzoic acid
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.061
2-(2-methyl-1H-indol-3-yl)-2-oxo-N-phenylacetamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1853
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
Streptococcus mutans
pH 7.2, 37°C, recombinant enzyme
0.301
2-(3,5-dichlorophenyl)-4-(ethylsulfanyl)-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.166
2-(3,5-dichlorophenyl)-5-ethoxy-4-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
2-(3-bromophenyl)-4,5-dichloropyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
2-(3-bromophenyl)-4-(ethylsulfanyl)-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
2-(3-bromophenyl)-4-chloro-5-ethoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
2-(3-bromophenyl)-5-chloro-4-ethoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
2-(3-bromophenyl)-5-chloro-4-methoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0045
2-(3-chlorophenyl)-4-methoxy-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.00611
2-(3-oxo-1,2-benzothiazol-2(3H)-yl)-N-(tricyclo[3.3.1.13,7]dec-1-yl)acetamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA59
0.0152
2-(4-(1-cyanovinyl)phenyl)-N-isobutylbenzofuran-3-carboxamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.05
2-(4-nitrophenyl)-4,5-dichloropyridazin-3-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.015
2-(4-[2-[4-(benzyloxy)phenyl]-1-cyanoethyl]phenyl)-N-(2-methylpropyl)-1-benzofuran-3-carboxamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.058
2-(morpholin-4-yl)-5-[[(2E)-3-(thiophen-2-yl)prop-2-enoyl]amino]benzoic acid
Staphylococcus aureus
-
pH 7.5, 37°C
0.0179
2-cyclohexyl-4-(ethylsulfanyl)-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
2-ethyl-4-hydroxy-5-(methylsulfanyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0625
2-hydroxy-5-[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]-4-(propan-2-yl)cyclohepta-2,4,6-trien-1-one
Streptococcus mutans
pH 7.2, 37°C, recombinant enzyme
0.226
2-hydroxy-N-[4-[([[(4-methylphenyl)sulfonyl]amino]carbonyl)amino]phenyl]benzamide
Staphylococcus aureus
-
-
0.105
2-morpholin-4-yl-5-[[(2E)-3-(2-thienyl)prop-2-enoyl]amino]benzamide
Staphylococcus aureus
-
-
0.05
2-phenyl-4,5-dichloro-pyridazin-3-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.06
2-[2-[(4-fluorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]-N-(6-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0088
2-[4-(1-cyano-2-phenylethyl)phenyl]-N-(2-methylpropyl)-1-benzofuran-3-carboxamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0137
2-[4-[1-cyano-2-(3,4-dihydroxyphenyl)ethyl]phenyl]-N-(2-methylpropyl)-1-benzofuran-3-carboxamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0079
2-[4-[1-cyano-2-(4-hydroxyphenyl)ethyl]phenyl]-N-(2-methylpropyl)-1-benzofuran-3-carboxamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0161
3',3''-dihydroxy-(-)-matairesinol
0.19
3,3,3-trifluoro-1-(phenylsulfonyl)-1-propene
Staphylococcus aureus
-
IC50: 0.19 mM, irreversible
0.3
3,4-bis[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
Streptococcus mutans
above, pH 7.2, 37°C, recombinant enzyme
0.0973
3,5-bis[[2-(4-nitrophenyl)-2-oxoethyl]thio]isothiazole-4-carbonitrile
Staphylococcus aureus
-
-
0.0128
3-(3-oxo-1,2-benzothiazol-2(3H)-yl)propanoic acid
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA75
0.0548 - 0.0907
3-(dimethylamino)-1-(2-thienyl)propan-1-one
0.0543 - 0.0902
3-(dimethylamino)-1-(3-nitrophenyl)propan-1-one
0.066 - 0.0873
3-anilino-1-(3-nitrophenyl)propan-1-one
0.061
4,5-dichloro-2-(3,5-dichlorophenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
4,5-dichloro-2-(3-fluorophenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
4,5-dichloro-2-(3-methylphenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
4,5-dichloro-2-cyclohexylpyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.009
4-(5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)morpho-line
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.05
4-(benzyloxy)-5-hydroxy-2-phenylpyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM,
0.0055
4-(ethylsulfanyl)-2-(3-fluorophenyl)-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0033
4-(ethylsulfanyl)-2-(3-methylphenyl)-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.03
4-(ethylsulfanyl)-2-(4-nitrophenyl)-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0014
4-(ethylsulfanyl)-2-phenyl-5-sulfanylpyridazin-3(2H)-one
0.05
4-(ethylsulfanyl)-5-hydroxy-2-phenylpyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM,
0.0059
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.05
4-chloro-2-(3,5-dichlorophenyl)-5-ethoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
4-chloro-2-cyclohexyl-5-ethoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
4-chloro-5-(methylsulfanyl)-2-phenylpyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
4-chloro-5-ethoxy-2-(3-fluorophenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
4-chloro-5-ethoxy-2-(3-methylphenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.219
4-chloro-5-ethoxy-2-(4-nitrophenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.001
4-chloro-5-ethoxy-2-phenylpyridazin-3-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0002
4-ethoxy-2-phenyl-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.013
4-ethoxy-5-mercapto-2-phenylpyridazin-3-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
4-hydroxy-5-(methylsulfanyl)-2-phenylpyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.1125
4-hydroxymercuribenzoate
Streptococcus mutans
-
pH and temperature not specified in the publication
0.521
5-((3-nitrobenzyl)thio)-1,3,4-thiadiazol-2-amine
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.026
5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-amine
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.026
5-((C4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-amine
Staphylococcus aureus
-
pH and temperature not specified in the publication
-
0.05
5-chloro-2-(3,5-dichlorophenyl)-4-ethoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-2-(3,5-dichlorophenyl)-4-methoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-2-(3-fluorophenyl)-4-methoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-2-cyclohexyl-4-ethoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-2-cyclohexyl-4-methoxypyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-4-ethoxy-2-(3-fluorophenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-4-ethoxy-2-(3-methylphenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-4-ethoxy-2-(4-nitrophenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-4-ethoxy-2-phenylpyridazin-3-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-4-methoxy-2-(3-methylphenyl)pyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-chloro-4-methoxy-2-phenylpyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM, in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0057
5-ethoxy-2-(3-fluorophenyl)-4-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0031
5-ethoxy-2-(3-methylphenyl)-4-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0044
5-ethoxy-2-phenyl-4-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.05
5-hydroxy-4-methoxy-2-phenylpyridazin-3(2H)-one
Staphylococcus aureus
-
IC50 above 0.05 mM,
0.0093
5-methoxy-2-phenyl-4-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.00037
5-[(2E)-3-(4-methoxyphenyl)prop-2-en-1-ylidene]-1,3-diazinane-2,4,6-trione
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0062
5-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]-1,3,4-thiadiazol-2-amine
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.181
5-[[(2E)-3-(2-furyl)prop-2-enoyl]amino]-2-morpholin-4-ylbenzoic acid
Staphylococcus aureus
-
-
0.02798
6-amino-7'-fluoro-2-(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)spiro[[1,3] dithiine-4,11'7-indeno[1,2-b]quinoxaline]-5-carbonitrile
Staphylococcus aureus
-
recombinant enzyme, pH 7.5, 37°C
0.03198
6-amino-7'-fluoro-2-(2-oxocycloheptylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
Staphylococcus aureus
-
recombinant enzyme, pH 7.5, 37°C
0.02215
6-amino-7'-fluoro-2-(3-methyl-5-oxo-1-phenyl-1H-pyrazol-4(5H)ylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
Staphylococcus aureus
-
recombinant enzyme, pH 7.5, 37°C
0.067
6-hydroxydihydro-beta-carboline
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.03712
7'-fluoro-6-hydroxy-2-(2-oxocyclohexylidene)spiro[[1,3]dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carbonitrile
Staphylococcus aureus
-
recombinant enzyme, pH 7.5, 37°C
0.0115
7-methoxy-1-phenyl-2,3,4,9-tetrahydro-1H-beta-carboline
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.025
7-methoxy-1-phenyl-4,9-dihydro-3H-beta-carboline
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.146
aspermytin A
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.01665
astilbin
Streptococcus mutans
-
pH and temperature not specified in the publication
0.0015
bis(4-ethoxy-2-phenyl-5-pyridazyl)disulfide
Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.00113
cis-1,2-bis(phenylsulfonyl)ethylene
Staphylococcus aureus
-
IC50: 0.00113 mM, irreversible
0.0915
curcumin
Streptococcus mutans
-
pH and temperature not specified in the publication
0.07628
cyanidin chloride
Staphylococcus aureus
-
pH and temperature not specified in the publication
-
0.00106
divinyl sulfone
Staphylococcus aureus
-
IC50: 0.00106 mM, irreversible
0.0657
erianin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0802 - 0.0907
ethyl 4-[3-(4-bromophenyl)-3-oxopropyl]piperazine-1-carboxylate
0.0247
ethyl 6-amino-7'-fluoro-2-(3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)spiro[[1,3] dithiine-4,11'-indeno[1,2-b]quinoxaline]-5-carboxylate
Staphylococcus aureus
-
recombinant enzyme, pH 7.5, 37°C
0.00471
ethyl vinyl sulfone
Staphylococcus aureus
-
IC50: 0.00471 mM, irreversible
0.123
galangin
Staphylococcus aureus
-
IC50 for recombinant SrtA(DELTA24): 0.123 mM, no antibacterial activity against Staphylococcus aureus
0.1179
galangin-3-methyl ether
Staphylococcus aureus
-
IC50 for recombinant SrtA(DELTA24): 0.1179 mM, no antibacterial activity against Staphylococcus aureus
0.032145
genistin
Listeria monocytogenes
-
pH and temperature not specified in the publication
0.06311
hibifolin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.05886
isorhamnetin
Staphylococcus aureus
-
IC50 for recombinant SrtA(DELTA24): 0.05886 mM, no antibacterial activity against Staphylococcus aureus
0.0621
isorhamnetin 3-O-beta-D-rutinoside
Streptococcus mutans
-
pH and temperature not specified in the publication
0.05717
isovitexin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.00178
juglone
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.07794
kaempferol
Staphylococcus aureus
-
IC50 for recombinant SrtA(DELTA24): 0.07794 mM, no antibacterial activity against Staphylococcus aureus
0.0607
kaempferol-3-rutinoside
Streptococcus mutans
-
pH and temperature not specified in the publication
0.0189
L-leucyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1363
L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonylprolinamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1369
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-phenylalaninamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1369
L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0189
L-leucyl-L-prolyl-N-[(2S)-5-[(2-amino-2-oxoethyl)(methyl)amino]-1-carboxy-3,5-dioxopentan-2-yl]-N5-(diaminomethylidene)-L-ornithinamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1853
L-phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0189
LPRDSar
Staphylococcus aureus
-
pH and temperature not specified in the publication
-
0.0943
maltol 3-O-(4'-O-p-coumaroyl-6'-O-(3-hydroxy-3-methylglutaroyl))-beta-glucopyranoside
Streptococcus mutans
-
pH and temperature not specified in the publication
0.0586
maltol-3-O-(4'-O-cis-p-coumaroyl-6'-O-(3-hydroxy-3-methylglutaroyl))-beta-glucopyranoside
Streptococcus mutans
-
pH and temperature not specified in the publication
0.231
methyl (2E)-2,3-bis(4-methoxyphenyl)acrylate
Staphylococcus aureus
-
IC50: 0.231 mM
0.231
methyl (2E)-3-(4-methoxycyclohexa-2,4-dien-1-yl)-2-(4-methoxyphenyl)prop-2-enoate
Staphylococcus aureus
-
pH 7.5, 37°C
2.2
methyl (2S,3S,7aS)-2-ethenesulfonyl-5-oxo-3-phenyltetrahydropyrrolizine-7a-carboxylate
Staphylococcus aureus
-
pH 7.5, 37°C
2.47
methyl (2S,3S,7aS)-2-ethenesulfonyl-5-oxo-3-pyridin-3-yl-tetrahydropyrrolizine-7a-carboxylate
Staphylococcus aureus
-
pH 7.5, 37°C
2.68
methyl (2S,3S,7aS)-3-(3,4-dimethoxyphenyl)-2-ethenesulfonyl-5-oxotetrahydropyrrolizine-7a-carboxylate
Staphylococcus aureus
-
pH 7.5, 37°C
1.86
methyl (2S,4S,5S)-4-ethenesulfonyl-2-(2-methoxycarbonylethyl)-5-pyridin-3-yl-pyrrolidine-2-carboxylate
Staphylococcus aureus
-
pH 7.5, 37°C
0.909
methyl (2Z)-2,3-bis(4-methoxyphenyl)acrylate
Staphylococcus aureus
-
IC50: 0.909 mM
1.32
methyl (4S,5S)-4-(ethenylsulfonyl)-5-(2-fluorophenyl)-L-prolinate
Staphylococcus aureus
-
pH 7.5, 37°C
1.04
methyl (4S,5S)-4-(ethenylsulfonyl)-5-(3-fluorophenyl)-L-prolinate
Staphylococcus aureus
-
pH 7.5, 37°C
0.85
methyl (4S,5S)-4-(ethenylsulfonyl)-5-phenyl-L-prolinate
Staphylococcus aureus
-
pH 7.5, 37°C
0.071
methyl 2-morpholin-4-yl-5-[[(2E)-3-(2-thienyl)prop-2-enoyl]amino]benzoate
Staphylococcus aureus
-
-
0.00508
methyl 3-(3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamido)adamantane-1-carboxylate
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA66
0.00506
methyl 3-(3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamido)adamantane-1-carboxylate
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA71
0.0698 - 0.0913
methyl 4-[3-(dimethylamino)propanoyl]benzenesulfinate
0.058
methyl 5-[[(2E)-3-(2-furyl)prop-2-enoyl]amino]-2-morpholin-4-ylbenzoate
Staphylococcus aureus
-
-
0.075
methyl 5-[[(2E)-3-(furan-2-yl)prop-2-enoyl]amino]-2-(morpholin-4-yl)benzoate
Staphylococcus aureus
-
pH 7.5, 37°C
0.00624
methyl vinyl sulfone
Staphylococcus aureus
-
IC50: 0.00624 mM, irreversible
0.03739
morin
Staphylococcus aureus
-
IC50 for recombinant SrtA(DELTA24): 0.03739 mM, no antibacterial activity against Staphylococcus aureus
0.04403 - 0.04866
myricetin
0.0038
N'-(2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetyl)adamantane-1-carbohydrazide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA72
0.00422
N'-(3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanoyl)adamantane-1-carbohydrazide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA73
0.00339
N'-(3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanoyl)adamantane-1-carbohydrazide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA74
0.2071
N-(1H-benzimidazol-5-yl)acridin-9-amine
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.00499
N-(3,5-dimethyladamantan-1-yl)-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA60
0.00462
N-(3,5-dimethyladamantan-1-yl)-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA63
0.0041
N-(3,5-dimethyladamantan-1-yl)-3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA68
0.00387
N-(3-hydroxy-5,7-dimethyladamantan-1-yl)-2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA61
0.00706
N-(3-hydroxy-5,7-dimethyladamantan-1-yl)-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA64
0.00396
N-(3-hydroxy-5,7-dimethyladamantan-1-yl)-3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA69
0.00644
N-(3-hydroxyadamantan-1-yl)-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA65
0.00626
N-(3-ydroxyadamantan-1-yl)-3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA70
0.127
N-(5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)acetamide
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.042
N-(5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)isonicotinamide
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.0038
N-(5-((4-nitrobenzyl)thio)-1,3,4-thiadiazol-2-yl)nicotinamide
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.03
N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-5-nitro-N-[(pyridin-3-yl)methyl]oxolane-2-carboxamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0038
N-(5-[[(4-nitrophenyl)methyl]sulfanyl]-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.00401
N-(adamantan-1-yl)-3-(4-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA67
0.00381
N-adamantan-1-yl-3-(3-oxobenzo[d]isothiazol-2(3H)-yl)propanamide
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA62
0.0574
N-benzoyl-L-leucyl-L-prolyl-L-alpha-glutamyl-L-threonyl-L-prolinamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1138
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-phenylalaninamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0574
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-N2-methylglycinamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1138
N-benzoyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartylphenylalaninamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.07
N-benzyl-N-(5-methoxy-2,3-dihydro-1H-inden-2-yl)-5-nitrooxolane-2-carboxamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.16
N1,N1-diethyl-N3-[2-(4-nitrophenyl)quinazolin-4-yl]propane-1,3-diamine
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.05044
orientin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1605
oroxylin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.042
p-hydroxymercuribenzoic acid
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.01061
PEG200-L-leucyl-D-prolyl-N5-(diaminomethylidene)-L-ornithyl-L-alpha-aspartyl-L-alaninamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0169 - 0.736
phenyl vinyl sulfone
0.1853
phenylalanyl-L-leucyl-L-prolyl-L-arginyl-L-alpha-aspartyl-L-alaninamide
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.01071
Plumbagin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0039
punicalagin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0527 - 0.2108
quercetin
0.05361
quercetin-3,3'-dimethyl ether
Staphylococcus aureus
-
IC50 for recombinant SrtA(DELTA24): 0.05361 mM, no antibacterial activity against Staphylococcus aureus
0.03218 - 0.1859
quercitrin
0.05096
rhodionin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.02453
taxifolin
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0253
triphasiol
Streptococcus mutans
pH 7.2, 37°C, recombinant enzyme
-
0.1857
wogonin
Streptococcus pneumoniae
-
pH and temperature not specified in the publication
additional information
additional information
-
0.0141
(Z)-2-(4-(1-cyano-2-(2,5-methoxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide

Staphylococcus aureus
-
pH 7.5, 37°C
0.0218
(Z)-2-(4-(1-cyano-2-(2,5-methoxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0033
(Z)-2-(4-(1-cyano-2-(3,4-benzyloxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide

Staphylococcus aureus
-
pH 7.5, 37°C
0.0096
(Z)-2-(4-(1-cyano-2-(3,4-benzyloxyphenyl)vinyl)phenyl)-N-isobutylamine benzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0164
(Z)-2-(4-(1-cyano-2-(4-bromophenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide

Staphylococcus aureus
-
pH 7.5, 37°C
0.1
(Z)-2-(4-(1-cyano-2-(4-bromophenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0059
(Z)-2-(4-(1-cyano-2-(4-chlorophenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide

Staphylococcus aureus
-
pH 7.5, 37°C
0.0101
(Z)-2-(4-(1-cyano-2-(4-chlorophenyl)vinyl)phenyl)-N-isobutylamine-3-methoxybenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0138
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide

Staphylococcus aureus
-
pH 7.5, 37°C
0.0155
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0641
(Z)-2-(4-(1-cyano-2-(4-methoxyphenyl)vinyl)phenyl)-N-isobutylamine-5-chlorobenzofuran-3-formamide
Staphylococcus aureus
-
pH 7.5, 37°C
0.0896
1-(3,4-dichlorophenyl)-3-(dimethylamino)propan-1-one

Staphylococcus aureus
-
-
0.0904
1-(3,4-dichlorophenyl)-3-(dimethylamino)propan-1-one
Staphylococcus aureus
-
-
0.736
1-(3,4-dichlorophenyl)-3-(dimethylamino)propan-1-one
Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA75
0.0569
1-(4-bromophenyl)-3-(3-methylpiperidin-1-yl)propan-1-one

Staphylococcus aureus
-
-
0.0837
1-(4-bromophenyl)-3-(3-methylpiperidin-1-yl)propan-1-one
Staphylococcus aureus
-
-
0.0844
1-(4-chlorophenyl)-3-morpholin-4-ylpropan-1-one

Staphylococcus aureus
-
-
0.0906
1-(4-chlorophenyl)-3-morpholin-4-ylpropan-1-one
Staphylococcus aureus
-
-
0.0472
1-(4-fluorophenyl)-3-morpholin-4-ylpropan-1-one

Staphylococcus aureus
-
-
0.0891
1-(4-fluorophenyl)-3-morpholin-4-ylpropan-1-one
Staphylococcus aureus
-
-
0.0569
1-(4-methylphenyl)-3-morpholin-4-ylpropan-1-one

Staphylococcus aureus
-
-
0.0889
1-(4-methylphenyl)-3-morpholin-4-ylpropan-1-one
Staphylococcus aureus
-
-
0.0161
3',3''-dihydroxy-(-)-matairesinol

Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0161
3',3''-dihydroxy-(-)-matairesinol
Streptococcus mutans
-
pH and temperature not specified in the publication
0.0161
3',3''-dihydroxy-(-)-matairesinol
Streptococcus mutans
pH 7.2, 37°C, recombinant enzyme
0.0548
3-(dimethylamino)-1-(2-thienyl)propan-1-one

Staphylococcus aureus
-
-
0.0907
3-(dimethylamino)-1-(2-thienyl)propan-1-one
Staphylococcus aureus
-
-
0.0543
3-(dimethylamino)-1-(3-nitrophenyl)propan-1-one

Staphylococcus aureus
-
-
0.0902
3-(dimethylamino)-1-(3-nitrophenyl)propan-1-one
Staphylococcus aureus
-
-
0.066
3-anilino-1-(3-nitrophenyl)propan-1-one

Staphylococcus aureus
-
-
0.0873
3-anilino-1-(3-nitrophenyl)propan-1-one
Staphylococcus aureus
-
-
0.0014
4-(ethylsulfanyl)-2-phenyl-5-sulfanylpyridazin-3(2H)-one

Staphylococcus aureus
-
in 20 mM HEPES, 5 mM CaCl2, 0.05% (v/v) Tween-20, pH 7.5, at 25°C
0.0014
4-(ethylsulfanyl)-2-phenyl-5-sulfanylpyridazin-3(2H)-one
Staphylococcus aureus
-
pH 8.0, 23°C, recombinant enzyme
0.0802
ethyl 4-[3-(4-bromophenyl)-3-oxopropyl]piperazine-1-carboxylate

Staphylococcus aureus
-
-
0.0907
ethyl 4-[3-(4-bromophenyl)-3-oxopropyl]piperazine-1-carboxylate
Staphylococcus aureus
-
-
0.0698
methyl 4-[3-(dimethylamino)propanoyl]benzenesulfinate

Staphylococcus aureus
-
-
0.0913
methyl 4-[3-(dimethylamino)propanoyl]benzenesulfinate
Staphylococcus aureus
-
-
0.04403
myricetin

Staphylococcus aureus
-
IC50 for recombinant SrtA(DELTA24): 0.04403 mM, no antibacterial activity against Staphylococcus aureus
0.04866
myricetin
Streptococcus mutans
-
pH and temperature not specified in the publication
0.0169
phenyl vinyl sulfone

Staphylococcus aureus
-
pH 7.5, 37°C, recombinant His6-tagged truncated enzyme mutant variant SrtADELTA75
0.736
phenyl vinyl sulfone
Staphylococcus aureus
-
IC50: 0.736 mM, irreversible
0.0527
quercetin

Staphylococcus aureus
-
IC50 for recombinant SrtA(DELTA24): 0.0527 mM, no antibacterial activity against Staphylococcus aureus
0.2108
quercetin
Streptococcus mutans
-
pH and temperature not specified in the publication
0.03218
quercitrin

Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1859
quercitrin
Streptococcus mutans
-
pH and temperature not specified in the publication
0.05384
rutin

Streptococcus agalactiae
-
pH and temperature not specified in the publication
0.1341
rutin
Streptococcus mutans
-
pH and temperature not specified in the publication
additional information
additional information

Staphylococcus aureus
-
IC50 for aaptamine is 0.0235 mg/ml, IC50 for isoaaptamine is 0.0037 mg/ml, IC50 for demethylaaptamine is 0.0172 mg/ml, IC50 for demethyloxyaaptamine is 0.0201 mg/ml, IC50 for berberine chloride is 0.0087 mg/ml
-
additional information
additional information
Lactobacillus acidophilus
-
IC50 for phenyl vinyl sulfone is 0.14332 mg/ml
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.